Mycophenolate Mofetil

English name mycophenolate mofetil

also known as MMF · CellCept · mycophenolate mofetil (MMF) · Mycophenolat Mofetil · Mycophenylate mofetil · Mycophénolate mofétil = Cellcept · Mycofenolate mofetil · MPM · +15 more

Small molecule

Developed for: myelodysplastic syndrome · lupus nephritis · acute myeloid leukemia · chronic myeloid leukemia · graft versus host disease · disease related to solid organ transplantation · systemic sclerosis · disease related to hematopoietic stem cell transplant
+95 more
· IgA glomerulonephritis · interstitial lung disease · HIV infectious disease · chronic renal failure syndrome · end stage renal failure · systemic lupus erythematosus · acute graft versus host disease · autoimmune hepatitis · B-cell chronic lymphocytic leukemia · chronic myelomonocytic leukemia · diabetic kidney disease · granulomatosis with polyangiitis · immunoglobulin A vasculitis · membranous glomerulonephritis · post-transplant lymphoproliferative disease · prolymphocytic leukemia · alcoholic hepatitis · anti-neutrophil cytoplasmic antibody-associated vasculitis · astrocytoma (excluding glioblastoma) · autoimmune disease · chronic graft versus host disease · focal segmental glomerulosclerosis · generalized myasthenia gravis · idiopathic membranous glomerulonephritis · immunodeficiency disease · impaired renal function disease · liver failure · multiple sclerosis · myelofibrosis · nephrotic syndrome · pemphigus vulgaris · renal hypertension · rheumatoid arthritis · Sjogren syndrome · transplant rejection · type 1 diabetes mellitus · acquired aplastic anemia · acute transplant rejection · aplastic anemia · atopic eczema · autoimmune thrombocytopenia · autoimmune thrombocytopenic purpura · autosomal recessive disease · bullous pemphigoid · cardiovascular disorder · chronic inflammatory demyelinating polyradiculoneuropathy · chronic kidney disease · chronic transplant rejection · corneal disorder · diffuse cutaneous systemic sclerosis · fibrotic hypersensitivity pneumonitis · glioblastoma · gliosarcoma · gout · Graves disease · hepatitis · hepatitis B virus infection · hepatitis C virus infection · IDH-wildtype glioblastoma · idiopathic inflammatory myopathy · idiopathic nephrotic syndrome · immunoglobulin G4-related sclerosing disease · intrinsic cardiomyopathy · limited cutaneous systemic sclerosis · liver diffuse large B-cell lymphoma · liver disorder · malignant pancreatic neoplasm · microscopic polyangiitis · mucous membrane pemphigoid · myasthenia gravis · myocarditis · neuromyelitis optica · primary biliary cholangitis · psoriasis · pulmonary systemic sclerosis · purine nucleoside phosphorylase deficiency · scleroderma · severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency · sinus histiocytosis with massive lymphadenopathy · small cell lung carcinoma · uveitis · vasculitis · arthritic joint disease · autoimmune hemolytic anemia · cytomegalovirus infection · drug-induced hepatitis · hepatocellular carcinoma · infectious disease · interstitial cystitis · juvenile neuronal ceroid lipofuscinosis · keratopathy · nephritis · primary focal segmental glomerulosclerosis · pure red-cell aplasia · urogenital tract malformation
Investigated by: Hoffmann-La Roche · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · Fred Hutchinson Cancer Center · National Institute of Allergy and Infectious Diseases (NIAID) · Aspreva Pharmaceuticals
+248 more
· Astellas Pharma Inc · Chong Kun Dang Pharmaceutical · Roche Pharma AG · Assistance Publique - Hôpitaux de Paris · Blood and Marrow Transplant Clinical Trials Network · M.D. Anderson Cancer Center · Novartis Pharmaceuticals · Peking Union Medical College Hospital · Seoul National University Hospital · Teva Pharmaceuticals USA · University Hospital, Limoges · Alliance for Clinical Trials in Oncology · Bristol-Myers Squibb · Children's Hospital Medical Center, Cincinnati · Genzyme, a Sanofi Company · Hospital Authority, Hong Kong · Masonic Cancer Center, University of Minnesota · Medical College of Wisconsin · National Marrow Donor Program · Pfizer · The University of Hong Kong · University Hospital Muenster · University of Michigan · Zhi-Hong Liu, M.D. · Astellas Pharma Global Development, Inc. · Autoimmunity Centers of Excellence · Beijing Friendship Hospital · CareDx · First Affiliated Hospital Xi'an Jiaotong University · Genentech, Inc. · Guangdong Provincial People's Hospital · H. Lee Moffitt Cancer Center and Research Institute · Hannover Medical School · Incyte Corporation · Kyungpook National University Hospital · Leiden University Medical Center · Mayo Clinic · Michael Roth · Nanfang Hospital, Southern Medical University · Nanjing University School of Medicine · National Center for Research Resources (NCRR) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Neovii Biotech · Northwestern University · Post Graduate Institute of Medical Education and Research, Chandigarh · Radboud University Medical Center · Rho Federal Systems Division, Inc. · Stanford University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Third Affiliated Hospital, Sun Yat-Sen University · Tongji Hospital · University College, London · University Hospital Schleswig-Holstein · University of California, San Francisco · University of Cincinnati · University of Florida · University of Maryland, Baltimore · University of Oslo School of Pharmacy · University of Washington · University of Wisconsin, Madison · Washington University School of Medicine · Wyeth is now a wholly owned subsidiary of Pfizer · Yonsei University · Aaron Boster · Academic Medical Center - University of Amsterdam · Achillion, a wholly owned subsidiary of Alexion · Agenzia Italiana del Farmaco · Ajou University School of Medicine · Albert Einstein Healthcare Network · Alexion Pharmaceuticals, Inc. · Aravind Eye Hospitals, India · Asan Medical Center · Asociación para Evitar la Ceguera en México · Astellas Pharma Canada, Inc. · all 254 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (4)	US (FDA)	CELLCEPT	—	1998-02-11 – 2022-06-06	fda.gov ↗
Approved	EU (EMA)	CellCept	—	1996-02-14	europa.eu ↗
Approved	US (FDA)	CELLCEPT	—	1995-05-03	fda.gov ↗

Trials 248 · started per year

today

US approved 1995

EU approved 1996

1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT00618527	Aug 2006 → May 2012	multiple sclerosis	Aaron Boster	Completed	No outcome recorded
Phase 0	NCT00187941	Aug 2005 → Nov 2006	—	University of Florida	Completed	No outcome recorded
Phase 126 trials
Phase 1	NCT06996119	Jun 2026 → May 2027 expected	acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 1	NCT05049863	Feb 2023 → Nov 2024	small cell lung carcinoma	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT05236036	Aug 2022 → Jan 2026 overdue	IDH-wildtype glioblastoma, astrocytoma (excluding glioblastoma)	Northwestern University	Active not recruiting	No outcome recorded
Phase 1	NCT04868786	Oct 2020 → Jul 2025	disease related to hematopoietic stem cell transplant	Seoul National University Hospital	Unknown	No outcome recorded
Phase 1	NCT04477200	Aug 2020 → Jan 2025 overdue	astrocytoma (excluding glioblastoma), gliosarcoma	University of Michigan Rogel Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT04039373	Jul → Sep 2019	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT03108274	Apr → Jun 2017	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03018223	Jan 2017 → Dec 2018	Hodgkins lymphoma, acute leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +4	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 1	NCT02728700	Feb 2016 → Apr 2017	Hodgkins lymphoma, adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia +4	Stanford University	Terminated	No outcome recorded
Phase 1	NCT02743247	Oct 2015 → Apr 2016	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT01711489	Mar → Apr 2012	—	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 1	NCT00768729	May 2009 → Dec 2012	chronic renal failure syndrome	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT01364987	May → Jun 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT02981290	Jul → Oct 2008	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00433953	Feb 2007 → Feb 2010	—	Children's Hospital Medical Center, Cincinnati	Terminated	No outcome recorded
Phase 1	NCT00910663	Oct → Nov 2006	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00911274	Oct → Nov 2006	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00908128	Aug 2006	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00907907	Jul → Aug 2006	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00433186	Mar 2006 → Mar 2011	diffuse cutaneous systemic sclerosis	Boston University	Completed	No outcome recorded
Phase 1	NCT00997958	Jun 2004 → Oct 2007	malignant pancreatic neoplasm	Columbia University	Completed	No outcome recorded
Phase 1	NCT00405860	Dec 2002 → Jul 2008	microscopic polyangiitis	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT00255710	Jul 2002 → ?	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT00531635	Jul 2002 → Jun 2012	—	King Faisal Specialist Hospital & Research Center	Unknown	No outcome recorded
Phase 1	NCT00001764	Apr 1998 → Jun 2004	granulomatosis with polyangiitis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00008450	Aug 1997 → Oct 2011	autosomal recessive disease, purine nucleoside phosphorylase deficiency, severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency	Fred Hutchinson Cancer Center	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT05073822	Feb 2023 → Feb 2027	disease related to solid organ transplantation, transplant rejection	University College, London	Withdrawn	No outcome recorded
Phase 1/2	NCT03983850	Jul 2019 → Nov 2025 overdue	graft versus host disease, hematopoietic and lymphoid cell neoplasm	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT02432339	Apr 2014 → Nov 2019	renal hypertension	Augusta University	Unknown	No outcome recorded
Phase 1/2	NCT00085449	May 2006 → Jan 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Alliance for Clinical Trials in Oncology	Withdrawn	No outcome recorded
Phase 1/2	NCT00119340	Apr 2005 → Nov 2007	leukemia	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00078858	Sep 2003 → Jan 2006	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +33	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00027820	Aug 2001 → Sep 2004	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia +9	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 273 trials
Phase 2	NCT07663422	Jun 2026 → Mar 2028 expected	hepatitis	Fox Chase Cancer Center	Not yet recruiting	No outcome recorded
Phase 2	NCT07124078	May 2026 → Jan 2029 expected	chronic graft versus host disease	Incyte Corporation	Recruiting	No outcome recorded
Phase 2	NCT07340463	Dec 2025 → Jun 2027 expected	lupus nephritis, systemic lupus erythematosus	Nanjing University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT06859424	Jul 2025 → Jun 2028 expected	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3	Center for International Blood and Marrow Transplant Research	Recruiting	No outcome recorded
Phase 2	NCT06973668	Jul 2025 → Jan 2028 expected	acute myeloid leukemia	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT06828796	Jul 2025 → Jun 2027 expected	disease related to hematopoietic stem cell transplant, hematologic disorder	Northside Hospital, Inc.	Recruiting	No outcome recorded
Phase 2	NCT06872333	Nov 2024 → Jun 2030 expected	disease related to hematopoietic stem cell transplant, sickle cell disease	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05785065	Aug 2024 → Dec 2026 expected	interstitial lung disease, pulmonary systemic sclerosis	University of Montreal Hospital Centre (CHUM)	Recruiting	No outcome recorded
Phase 2	NCT05538208	Jun 2024 → Jul 2026 overdue	lupus nephritis	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT06412497	Jun 2024 → May 2035 expected	acquired thrombocytopenia, idiopathic aplastic anemia, paroxysmal nocturnal hemoglobinuria, primary acquired red cell aplasia	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05101447	Jul 2023 → Jan 2024	lupus nephritis	Children's Hospital Medical Center, Cincinnati	Withdrawn	No outcome recorded
Phase 2	NCT05306873	Nov 2022 → Jun 2024	systemic lupus erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT05293509	Mar 2022 → Sep 2023	disease related to hematopoietic stem cell transplant	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT05113004	Jan 2022 → Apr 2025 overdue	Sjogren syndrome	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 2	NCT04927390	Dec 2021 → Nov 2023	limited cutaneous systemic sclerosis	University College, London	Unknown	No outcome recorded
Phase 2	NCT05077254	Dec 2021 → Feb 2024	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT05000216	Aug 2021 → Jun 2023	juvenile dermatomyositis, juvenile idiopathic arthritis, pediatric multiple sclerosis, pediatric systemic lupus erythematosus +3	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT04415476	Jun 2020 → Jun 2024	chronic transplant rejection, immunodeficiency disease, transplant-related bronchiolitis obliterans	University of Maryland, Baltimore	Withdrawn	No outcome recorded
Phase 2	NCT03388008	Dec 2019 → Aug 2022	transplant rejection	Washington University School of Medicine	Completed	No outcome recorded
Phase 2	NCT03922724	Apr 2019 → Jun 2027 expected	lymphoproliferative syndrome, peripheral T-cell lymphoma, not otherwise specified	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT03303989	Jun 2018 → Apr 2020	gout	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 2	NCT03262441	Feb 2018 → Aug 2019	HIV infectious disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT03221257	Nov 2017 → Mar 2022	interstitial lung disease, systemic sclerosis	Michael Roth	Completed	No outcome recorded
Phase 2	NCT03246906	Sep 2017 → May 2025	CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia +9	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT02904772	Oct 2016 → Jun 2020	familial lipoprotein lipase deficiency	UniQure Biopharma B.V.	Withdrawn	No outcome recorded
Phase 2	NCT02861417	Aug 2016 → Aug 2026 overdue	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +4	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT02691949	Feb 2016 → Apr 2018	Sjogren syndrome	Kaohsiung Medical University	Unknown	No outcome recorded
Phase 2	NCT02137239	Dec 2015 → May 2019	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT02579967	Nov 2015 → Dec 2031 expected	T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT02593123	Nov 2015 → Mar 2022	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +2	Virginia Commonwealth University	Completed	No outcome recorded
Phase 2	NCT02532777	Aug 2015 → Jul 2020	immunoglobulin A vasculitis	Nanjing Children's Hospital	Unknown	No outcome recorded
Phase 2	NCT02949349	Jul 2015 → Dec 2016	lupus nephritis	Genovate Biotechnology Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT02458196	Apr 2015 → Jun 2017	autoimmune disease	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 2	NCT02220985	Mar 2015 → Apr 2025	CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, acute undifferentiated leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive +7	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01903798	Dec 2014 → Apr 2016	alcoholic hepatitis	Southern California Institute for Research and Education	Completed	No outcome recorded
Phase 2	NCT02294552	Oct 2014 → Nov 2016	acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome	Ivan S Moiseev	Completed	No outcome recorded
Phase 2	NCT02208037	Aug 2014 → Oct 2017	Hodgkins lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, diffuse large B-cell lymphoma +2	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT03200002	Jan 2014 → Jun 2015	—	Chitwan Medical College	Completed	No outcome recorded
Phase 2	NCT01946880	Nov 2013 → Jul 2019	systemic lupus erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT01898377	Aug 2013 → Feb 2018	chronic graft versus host disease	Seoul National University Hospital	Terminated	No outcome recorded
Phase 2	NCT01780844	Mar 2013 → Jun 2014	—	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 2	NCT01582048	Apr 2012 → Aug 2016	disease related to hematopoietic stem cell transplant	Prof. Dr. med. Wolfgang Bethge	Terminated	No outcome recorded
Phase 2	NCT01413100	Sep 2011 → Sep 2023	systemic sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01487577	Jun 2010 → Dec 2014	graft versus host disease	University of Pittsburgh	Completed	No outcome recorded
Phase 2	NCT00883129	Sep 2009 → Jan 2015	interstitial lung disease, scleroderma	Michael Roth	Completed	No outcome recorded
Phase 2	NCT00548717	Oct 2007 → Sep 2013	graft versus host disease	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT00551291	Aug 2007 → Jun 2009	myelodysplastic syndrome	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT01292226	Dec 2006 → Sep 2008	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00506948	Sep 2006 → Oct 2010	leukemia, lymphoma, myelodysplastic syndrome	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00383448	Sep 2006 → Sep 2014	GM1 gangliosidosis, Krabbe disease, Sandhoff disease, Tay-Sachs disease +5	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT01220297	Aug 2006 → Aug 2010	Hodgkins lymphoma, acute graft versus host disease, leukemia, non-Hodgkin lymphoma	Stanford University	Terminated	No outcome recorded
Phase 2	NCT00446459	Apr 2006 → Nov 2008	IgA glomerulonephritis, chronic renal failure syndrome, diabetic kidney disease, renal hypertension	University of Washington	Completed	No outcome recorded
Phase 2	NCT00135694	Oct 2005 → Sep 2015	chronic hepatitis C virus infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00224874	Sep 2005 → Jan 2009	graft versus host disease	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00214266	Jan 2005 → Aug 2007	—	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT00105001	Nov 2004 → May 2011	Burkitt lymphoma, Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia with t(9;11)(p22;q23) +17	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00096096	Aug 2004 → May 2006	acute graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00100178	May 2004 → Apr 2008	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00089011	Apr 2004 → Mar 2014	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +34	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00304720	Mar 2004 → ?	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Colorado Blood Cancer Institute	Unknown	No outcome recorded
Phase 2	NCT02630563	May 2003 → Jan 2005	—	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 2	NCT00053196	Dec 2002 → Nov 2006	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00693524	Nov 2002 → Mar 2004	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT00009009	Jan 2001 → Dec 2002	HIV infectious disease, chronic renal failure syndrome	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00005935	Jun 2000 → Mar 2002	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00295425	May 2000 → Oct 2006	psoriasis	University Hospital Muenster	Unknown	No outcome recorded
Phase 2	NCT00001964	Mar 2000 → Dec 2003	acquired aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00004567	Feb 2000 → Jun 2004	granulomatosis with polyangiitis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00006350	Jan 2000 → Nov 2001	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00431119	Oct 1997 → Oct 2000	bullous pemphigoid	University Hospital Muenster	Completed	No outcome recorded
Phase 2	NCT00038272	? → Apr 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00021489	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT01047072	? → Sep 2017	systemic sclerosis	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Withdrawn	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT07605364	Jun 2026 → Sep 2029 expected	glioblastoma	Alliance for Clinical Trials in Oncology	Not yet recruiting	No outcome recorded
Phase 2/3	NCT06068179	Oct 2023 → Oct 2025 overdue	Graves disease	The First Affiliated Hospital of Xiamen University	Recruiting	No outcome recorded
Phase 2/3	NCT05570409	Mar 2023 → Apr 2025	intrinsic cardiomyopathy	LMU Klinikum	Terminated	No outcome recorded
Phase 2/3	NCT04744623	Sep → Dec 2020	mucous membrane pemphigoid	Tanta University	Unknown	No outcome recorded
Phase 2/3	NCT00414128	Mar 2007 → Jul 2011	vasculitis	Cambridge University Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 2/3	NCT00223301	Jul 2004 → Mar 2007	multiple sclerosis	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 2/3	NCT00135967	May 2002 → ?	idiopathic membranous glomerulonephritis	Radboud University Medical Center	Completed	No outcome recorded
Phase 339 trials
Phase 3	NCT06297096	Jul 2025 → Dec 2027 expected	interstitial lung disease, systemic sclerosis	National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland	Recruiting	No outcome recorded
Phase 3	NCT06288932	Aug 2023 → Feb 2024	autoimmune thrombocytopenic purpura	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	Completed	No outcome recorded
Phase 3	NCT04531865	Jan 2021 → Sep 2022	nephrotic syndrome	Children's Hospital of Fudan University	Withdrawn	No outcome recorded
Phase 3	NCT05237323	Oct 2020 → Jul 2025	dilated cardiomyopathy, heart failure, myocarditis, sudden cardiac arrest	I.M. Sechenov First Moscow State Medical University	Completed	No outcome recorded
Phase 3	NCT03959241	Jun 2019 → Sep 2022	acute leukemia, chronic myeloid leukemia, lymphoma, myelodysplastic syndrome	Medical College of Wisconsin	Completed	No outcome recorded
Phase 3	NCT03156452	Oct 2017 → Mar 2020	autoimmune thrombocytopenia	University Hospitals Bristol and Weston NHS Foundation Trust	Completed	No outcome recorded
Phase 3	NCT02896205	Oct 2016 → Jul 2017	interstitial lung disease, systemic sclerosis	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 3	NCT03596970	Sep 2015 → Dec 2020	—	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 3	NCT01951885	Jul 2014 → Oct 2020	Hodgkins lymphoma, acute biphenotypic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +2	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 3	NCT02494505	Nov 2013 → May 2018	chronic inflammatory demyelinating polyradiculoneuropathy	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT01829295	Aug 2013 → Feb 2018	uveitis	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT01597778	Jun 2012 → Sep 2020	Burkitt lymphoma, Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia +2	Medical College of Wisconsin	Completed	No outcome recorded
Phase 3	NCT01282073	Mar 2011 → May 2016	membranous glomerulonephritis	Kyungpook National University Hospital	Completed	No outcome recorded
Phase 3	NCT01213394	Oct 2010 → Oct 2011	cardiovascular disorder	Ramesh Prasad	Terminated	No outcome recorded
Phase 3	NCT01092962	Sep 2010 → Feb 2015	idiopathic nephrotic syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT01014442	Jan 2010 → Jun 2012	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT01002742	Jan 2010 → Jan 2012	acute graft versus host disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 3	NCT01042457	May 2009 → Dec 2011	lupus nephritis	Chulalongkorn University	Completed	No outcome recorded
Phase 3	NCT02779114	Jan 2009 → Dec 2017	rheumatoid arthritis	University of Erlangen-Nürnberg Medical School	Unknown	No outcome recorded
Phase 3	NCT00604357	Dec 2008 → Jul 2011	impaired renal function disease, liver failure	University of Regensburg	Completed	No outcome recorded
Phase 3	NCT00425438	Mar 2007 → Apr 2008	lupus nephritis	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 3	NCT02091414	Aug 2006 → Feb 2009	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT02081183	Mar 2006 → Dec 2008	lupus nephritis	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 3	NCT00404794	Nov 2005 → Oct 2009	lupus nephritis, membranous glomerulonephritis	Hospital Authority, Hong Kong	Completed	No outcome recorded
Phase 3	NCT00377637	Jul 2005 → Mar 2007	lupus nephritis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00788567	Jun 2005 → May 2008	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00103792	Dec 2004 → Dec 2014	granulomatosis with polyangiitis	University Medical Center Groningen	Completed	No outcome recorded
Phase 3	NCT00321113	Sep 2004 → Mar 2008	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00683969	Aug 2004 → May 2007	generalized myasthenia gravis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00408213	Jun 2004 → Sep 2007	generalized myasthenia gravis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00683930	May 2004 → Oct 2008	pemphigus vulgaris	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00307645	May 2003 → Aug 2009	anti-neutrophil cytoplasmic antibody-associated vasculitis	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT00151632	May 2003 → Dec 2008	—	Rennes University Hospital	Terminated	No outcome recorded
Phase 3	NCT00693381	Feb 2003 → Aug 2004	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00404833	Jan 2003 → Dec 2006	focal segmental glomerulosclerosis, membranous glomerulonephritis	Hospital Authority, Hong Kong	Completed	No outcome recorded
Phase 3	NCT00285350	Sep 2002 → Mar 2007	myasthenia gravis	FDA Office of Orphan Products Development	Completed	No outcome recorded
Phase 3	NCT00140543	Feb 2002 → Sep 2005	diabetic kidney disease, type 1 diabetes mellitus	EUROSPK Study Group	Completed	No outcome recorded
Phase 3	NCT00204022	Feb 2001 → Aug 2011	lupus nephritis	Frédéric A. Houssiau, MD, PhD	Completed	No outcome recorded
Phase 3	NCT00461825	Jul 1998 → Feb 2007	—	Poitiers University Hospital	Completed	No outcome recorded

Phase 463 trials
Phase 4	NCT06354179	Apr 2025 → Apr 2028 expected	—	University Hospital, Limoges	Recruiting	No outcome recorded
Phase 4	NCT06676384	Feb 2025 → Aug 2029 expected	IgA glomerulonephritis, chronic kidney disease, immunoglobulin A vasculitis	Christian Medical College, Vellore, India	Recruiting	No outcome recorded
Phase 4	NCT06493526	Aug 2024 → Dec 2026 expected	—	University Hospital, Antwerp	Recruiting	No outcome recorded
Phase 4	NCT05916781	Jul 2023 → Jul 2025 overdue	lupus nephritis, systemic lupus erythematosus	Chinese SLE Treatment And Research Group	Recruiting	No outcome recorded
Phase 4	NCT05626387	Nov 2022 → Sep 2026 expected	fibrotic hypersensitivity pneumonitis	Post Graduate Institute of Medical Education and Research, Chandigarh	Active not recruiting	No outcome recorded
Phase 4	NCT05495893	Jul 2022 → May 2025	lupus nephritis	Second Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 4	NCT05207358	Mar 2022 → Dec 2028 expected	lupus nephritis	Institutul Clinic Fundeni	Recruiting	No outcome recorded
Phase 4	NCT05221411	Jan 2022 → Jan 2023	autoimmune hepatitis	Leiden University Medical Center	Unknown	No outcome recorded
Phase 4	NCT04895423	Nov 2021 → Jul 2023	atopic eczema	National Medical Research Center for Children's Health, Russian Federation	Unknown	No outcome recorded
Phase 4	NCT05060991	Sep 2021 → Dec 2026 expected	COVID-19, immunodeficiency disease	University of California, Davis	Active not recruiting	No outcome recorded
Phase 4	NCT04933292	Jun 2021 → May 2022	autoimmune hepatitis, primary biliary cholangitis	Xiaoli Fan	Unknown	No outcome recorded
Phase 4	NCT04444843	Jan 2021 → Dec 2022	disease related to solid organ transplantation	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
Phase 4	NCT05129410	Dec 2020 → Nov 2022	idiopathic inflammatory myopathy, interstitial lung disease	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
Phase 4	NCT04424862	Jun 2020 → Feb 2021	—	Beijing Friendship Hospital	Completed	No outcome recorded
Phase 4	NCT03170323	Jul 2018 → Dec 2020	idiopathic membranous glomerulonephritis	Guangdong Provincial People's Hospital	Unknown	No outcome recorded
Phase 4	NCT03794492	Mar 2018 → Jul 2022	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 4	NCT02900443	Jan 2017 → Jun 2023	autoimmune hepatitis	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT02981212	Jun 2016 → Aug 2018	IgA glomerulonephritis	Yonsei University	Unknown	No outcome recorded
Phase 4	NCT02809079	Jan 2016 → Dec 2017	neuromyelitis optica	Third Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
Phase 4	NCT03968588	Jul 2014 → Nov 2016	disease related to solid organ transplantation	Ajou University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02221583	May 2014 → Feb 2015	end stage renal failure	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT02075242	Jan 2014 → Jan 2016	hepatitis B virus infection	Asan Medical Center	Unknown	No outcome recorded
Phase 4	NCT01895894	Sep 2013 → Dec 2016	nephrotic syndrome	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT01860183	May 2013 → Jun 2016	kidney failure	Clinical Hospital Merkur	Completed	No outcome recorded
Phase 4	NCT01842269	Jan 2013 → Apr 2015	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 4	NCT01680952	Sep 2012 → Jan 2016	—	Yonsei University	Completed	No outcome recorded
Phase 4	NCT01801280	Jan 2012 → Mar 2013	disease related to solid organ transplantation	Klemens Budde	Completed	No outcome recorded
Phase 4	NCT05284942	Oct 2011 → Jun 2022	Langerhans cell histiocytosis, sinus histiocytosis with massive lymphadenopathy	Tongji Hospital	Unknown	No outcome recorded
Phase 4	NCT01363752	Mar 2011 → Sep 2013	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT01203709	Aug 2010 → Dec 2012	lupus nephritis	Tuen Mun Hospital	Completed	No outcome recorded
Phase 4	NCT01134952	Jun 2010 → Dec 2014	hepatitis C virus infection	London Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT01056822	May 2010 → Apr 2013	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00943228	Feb 2010 → Feb 2012	acute transplant rejection	Nova Scotia Health Authority	Completed	No outcome recorded
Phase 4	NCT01766518	Nov 2009 → Apr 2014	—	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 4	NCT00991510	Aug 2009 → Oct 2010	—	Teva Branded Pharmaceutical Products R&D, Inc.	Terminated	No outcome recorded
Phase 4	NCT00862979	Feb 2009 → Mar 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00758602	Sep 2008 → Feb 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00717314	May 2008 → Jul 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00545402	Nov 2007 → Jul 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00812786	Jul 2007 → May 2011	—	University Hospital, Limoges	Completed	No outcome recorded
Phase 4	NCT00494741	May 2007 → Jul 2016	—	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 4	NCT00420472	Mar 2007 → ?	—	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 4	NCT00456235	Sep 2006 → Sep 2009	—	University Hospital, Limoges	Completed	No outcome recorded
Phase 4	NCT00206076	Aug 2006 → Jun 2009	liver disorder	Albert Einstein Healthcare Network	Completed	No outcome recorded
Phase 4	NCT01601821	Apr 2006 → Mar 2008	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00337493	Dec 2005 → Jan 2008	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00538265	May 2005 → Jan 2010	—	University Hospital, Toulouse	Completed	No outcome recorded
Phase 4	NCT00223028	Apr → Jul 2005	—	University Hospital Schleswig-Holstein	Completed	No outcome recorded
Phase 4	NCT00189150	Apr 2005 → Aug 2007	—	University of Michigan	Completed	No outcome recorded
Phase 4	NCT00120419	Apr 2005 → ?	HIV infectious disease	Academic Medical Center - University of Amsterdam	Unknown	No outcome recorded
Phase 4	NCT00217152	Mar 2005 → Aug 2007	—	Mayo Clinic	Terminated	No outcome recorded
Phase 4	NCT00656266	Nov 2004 → Nov 2005	impaired renal function disease, kidney failure, liver failure	Baylor College of Medicine	Terminated	No outcome recorded
Phase 4	NCT00087581	Jun 2004 → Sep 2007	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00223015	May 2004 → Apr 2005	—	University Hospital Schleswig-Holstein	Completed	No outcome recorded
Phase 4	NCT00556933	Apr 2004 → Apr 2011	end stage renal failure	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT00148252	Feb 2003 → Nov 2005	—	University of Oslo School of Pharmacy	Terminated	No outcome recorded
Phase 4	NCT00199667	Oct 2002 → ?	disease related to solid organ transplantation	University Hospital, Limoges	Unknown	No outcome recorded
Phase 4	NCT00195988	Sep 2002 → Jul 2006	—	Children's Memorial Health Institute, Poland	Completed	No outcome recorded
Phase 4	NCT00352092	Jun 2002 → Dec 2007	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00863252	Mar 2002 → Jun 2004	IgA glomerulonephritis	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00138970	Jan 2002 → Feb 2005	disease related to solid organ transplantation	University of Oslo School of Pharmacy	Completed	No outcome recorded
Phase 4	NCT00681213	May 2000 → Dec 2001	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00411515	—	corneal disorder	University Hospital Freiburg	Completed	No outcome recorded

Phase not applicable31 trials
—	NCT07675291	Jun 2026 → Dec 2028 expected	lupus nephritis	Nanfang Hospital, Southern Medical University	Not yet recruiting	No outcome recorded
—	NCT06789315	Jan 2025 → Jan 2026 overdue	alcoholic hepatitis	Institute of Liver and Biliary Sciences, India	Not yet recruiting	No outcome recorded
—	NCT06663618	Sep 2023 → Mar 2025 overdue	immunoglobulin G4-related sclerosing disease	Wen Zhang	Recruiting	No outcome recorded
—	NCT05951517	Jan 2023 → Dec 2026 expected	immunoglobulin A vasculitis	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Recruiting	No outcome recorded
—	NCT05423496	Aug 2022 → Feb 2023	—	CareDx	Withdrawn	No outcome recorded
—	NCT05789017	Jul 2022 → Dec 2024	autoimmune disease	Peking Union Medical College Hospital	Unknown	No outcome recorded
—	NCT02426502	Apr 2016 → Aug 2022	end stage renal failure	University of British Columbia	Unknown	No outcome recorded
—	NCT02487069	Jun 2015 → Jan 2020	acute leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Nanfang Hospital, Southern Medical University	Completed	No outcome recorded
—	NCT02540395	Mar 2015 → Oct 2020	disease related to solid organ transplantation	Prof. Dr. Petra Reinke	Completed	No outcome recorded
—	NCT01854814	Jul 2013 → Feb 2022	IgA glomerulonephritis	Fan Fan Hou	Completed	No outcome recorded
—	NCT01580865	May 2012 → Mar 2017	lupus nephritis	Ramathibodi Hospital	Completed	No outcome recorded
—	NCT01566006	Apr 2012 → Jun 2013	diabetic kidney disease	The Nazareth Hospital, Israel	Unknown	No outcome recorded
—	NCT01321112	Feb 2011 → Mar 2014	—	Pontificia Universidad Catolica de Chile	Unknown	No outcome recorded
—	NCT01269021	Nov 2010 → Oct 2013	IgA glomerulonephritis	Zhi-Hong Liu, M.D.	Completed	No outcome recorded
—	NCT01640743	Mar 2010 → Jun 2013	—	Fondazione IRCCS Policlinico San Matteo di Pavia	Completed	No outcome recorded
—	NCT01056237	Feb 2010 → Jun 2013	lupus nephritis	Zhi-Hong Liu, M.D.	Completed	No outcome recorded
—	NCT00956059	Sep 2009 → Dec 2012	focal segmental glomerulosclerosis	Xi'an Jiaotong University	Unknown	No outcome recorded
—	NCT00876616	Apr 2009 → May 2011	lupus nephritis	Zhi-Hong Liu, M.D.	Completed	No outcome recorded
—	NCT00333437	May 2006 → Jan 2009	systemic sclerosis	University of California, San Francisco	Completed	No outcome recorded
—	NCT00360685	Sep 2005 → Jan 2011	graft versus host disease, mucositis	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
—	NCT00359658	Nov 2004 → Jun 2008	—	Hannover Medical School	Completed	No outcome recorded
—	NCT00359814	Nov 2004 → Jun 2008	—	Hannover Medical School	Completed	No outcome recorded
—	NCT00563589	Aug 2003 → Dec 2008	graft versus host disease	Hospital Authority, Hong Kong	Unknown	No outcome recorded
—	NCT00187915	Jul 2003 → Nov 2004	—	University of Florida	Completed	No outcome recorded
—	NCT00301652	Jun 2003 → Apr 2004	anti-neutrophil cytoplasmic antibody-associated vasculitis	Nanjing University School of Medicine	Completed	No outcome recorded
—	NCT00166153	Jan 2003 → May 2005	—	Emory University	Terminated	No outcome recorded
—	NCT00023231	Feb 2001 → Aug 2004	end stage renal failure	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00014235	Dec 2000 → Feb 2005	Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, MALT lymphoma +37	Fred Hutchinson Cancer Center	Completed	No outcome recorded
—	NCT00204230	Oct 1999 → Sep 2002	chronic renal failure syndrome	University Hospital Muenster	Terminated	No outcome recorded
—	NCT00007059	Jun 1998 → ?	graft versus host disease	National Center for Research Resources (NCRR)	Completed	No outcome recorded
—	NCT00849238	—	liver diffuse large B-cell lymphoma	University of Wisconsin, Madison	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 581 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 010 trials
Phase 0	NCT07519005 Background	Jan → Feb 2026 overdue	liver failure	Xijing Hospital	Active not recruiting	No outcome recorded
Phase 0	NCT06949267 Background	Jun 2025 → Sep 2026 expected	acute graft versus host disease	Ruijin Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT04469842 Background	Dec 2023 → Jun 2027 expected	transplant-related bronchiolitis obliterans	Vanderbilt University Medical Center	Recruiting	No outcome recorded
Phase 0	NCT04726553 Comparator	Jan 2021 → Dec 2023	systemic lupus erythematosus	Oklahoma Medical Research Foundation	Unknown	No outcome recorded
Phase 0	NCT04776850 Background	Dec 2020 → Dec 2022	beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 0	NCT03426969 Background	Jan 2018 → Sep 2020	myelofibrosis, primary myelofibrosis	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 0	NCT02447055 Background	Dec 2015 → Jun 2016	plasma cell myeloma	Washington University School of Medicine	Withdrawn	No outcome recorded
Phase 0	NCT02653196 Background	Sep 2015 → Aug 2017	neuroepithelial neoplasm	Montefiore Medical Center	Terminated	No outcome recorded
Phase 0	NCT02181478 Background	Jul 2015 → Dec 2019	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +2	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 0	NCT02416674 Background	Mar 2015 → Feb 2025	abdominal wall malformation	Brigham and Women's Hospital	Unknown	No outcome recorded

Phase 146 trials
Phase 1	NCT07548983 Background	Apr 2026 → Dec 2027 expected	acute myeloid leukemia	OHSU Knight Cancer Institute	Recruiting	No outcome recorded
Phase 1	NCT07162038 Background	Nov 2025 → Nov 2030 expected	hematopoietic and lymphoid cell neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1	NCT05298358 Background	Nov 2022 → Nov 2024	systemic sclerosis	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 1	NCT05170828 Background	Sep 2022 → Mar 2024	T-lymphoblastic lymphoma, acute biphenotypic leukemia, acute undifferentiated leukemia, myelodysplastic syndrome	Ossium Health, Inc.	Withdrawn	No outcome recorded
Phase 1	NCT05247203 Background	May 2022 → Oct 2023	systemic lupus erythematosus	RemeGen Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05088356 Background	Sep 2021 → May 2028 expected	acute leukemia, chronic myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome	Stanford University	Active not recruiting	No outcome recorded
Phase 1	NCT04521946 Background	Jan 2021 → Dec 2022	anaplastic ependymoma, atypical teratoid rhabdoid tumor, central nervous system germ cell tumor, choroid plexus carcinoma +3	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT04375631 Background	Dec 2020 → Feb 2027 expected	acute undifferentiated leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT04473911 Background	Aug 2020 → Oct 2023	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, bone marrow failure syndrome +3	Zachariah Michael DeFilipp	Completed	No outcome recorded
Phase 1	NCT03249831 Background	Jan 2019 → Jan 2027 expected	sickle cell disease, thalassemia	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT03504241 Background	Jul 2018 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03320642 Background	Feb 2018 → Feb 2021	hematopoietic and lymphoid cell neoplasm	Incyte Corporation	Terminated	No outcome recorded
Phase 1	NCT03118492 Background	May 2017 → Apr 2027 expected	myelofibrosis	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT02867800 Background	Jul 2016 → Dec 2021	graft versus host disease, sickle cell disease	Monica Bhatia	Completed	No outcome recorded
Phase 1	NCT02678143 Background	Apr 2016 → Apr 2020	sickle cell disease	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT02548468 Background	Nov 2015 → Jan 2017	mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Withdrawn	No outcome recorded
Phase 1	NCT02423915 Background	Jul 2015 → Oct 2020	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT02446964 Background	Jun 2015 → May 2025	adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, myelodysplastic syndrome	City of Hope Medical Center	Completed	No outcome recorded
Phase 1	NCT02188719 Background	Dec 2014 → Jun 2019	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 1	NCT02333162 Background	Dec 2014 → Dec 2028	acute myeloid leukemia, adult acute lymphoblastic leukemia, myelodysplastic syndrome	University of Chicago	Suspended	No outcome recorded
Phase 1	NCT01954784 Background	Oct 2013 → Jan 2017	plasma cell myeloma	Case Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 1	NCT01619761 Background	May 2013 → Nov 2021	Hodgkins lymphoma, acute biphenotypic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement +4	M.D. Anderson Cancer Center	Unknown	No outcome recorded
Phase 1	NCT00686556 Background	Aug 2012 → Nov 2016	acute lymphoblastic leukemia, myelodysplastic syndrome, plasma cell myeloma	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1	NCT01471067 Background	Jul 2012 → Apr 2017	disease related to hematopoietic stem cell transplant, leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01503242 Background	Jan 2012 → Jun 2017	plasma cell myeloma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01300572 Background	Jan 2012 → Oct 2017	acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01342289 Background	Aug 2011 → Mar 2018	Hodgkins lymphoma, leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT00988715 Background	Apr 2010 → Jan 2015	acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts +2	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1	NCT01041508 Background	Jan 2010 → Aug 2014	acute lymphoblastic leukemia, acute myeloid leukemia	Therapeutic Advances in Childhood Leukemia Consortium	Completed	No outcome recorded
Phase 1	NCT00972101 Background	Sep 2009 → Sep 2011	disease related to hematopoietic stem cell transplant, leukemia, lymphoma	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT01016626 Comparator	Jul → Aug 2009	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT00824135 Background	Jan 2009 → Oct 2012	hematopoietic and lymphoid cell neoplasm	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00589316 Background	Oct 2007 → Oct 2016	acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts +2	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00498316 Background	Jul 2007 → Oct 2016	leukemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00376519 Background	May 2007 → Mar 2008	graft versus host disease, leukemia, myelodysplastic syndrome, myelofibrosis +1	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 1	NCT00343798 Background	Apr 2006 → Jul 2013	Burkitt lymphoma, MALT lymphoma, acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with multilineage dysplasia +22	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00354419 Background	Feb 2006 → Dec 2010	aplastic anemia	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00301951 Background	Sep 2004 → Jul 2009	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00325741 Background	Jun 2004 → Oct 2015	systemic lupus erythematosus	Stanford University	Terminated	No outcome recorded
Phase 1	NCT00669890 Background	May 2004 → Dec 2012	acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome	New York Medical College	Terminated	No outcome recorded
Phase 1	NCT01020539 Background	Sep 2002 → Jul 2011	acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome	Columbia University	Completed	No outcome recorded
Phase 1	NCT00282412 Background	Sep 2002 → Jun 2016	rheumatoid arthritis	Northwestern University	Terminated	No outcome recorded
Phase 1	NCT00193635 Comparator	Mar 2002 → Aug 2007	urogenital tract malformation	Northwell Health	Completed	No outcome recorded
Phase 1	NCT00093743 Background	Jan 2000 → Sep 2007	Fanconi anemia, acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32) +4	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00006042 Background	Dec 1999 → ?	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT00008177 Background	Jul 1999 → Mar 2009	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32), acute myeloid leukemia, inv(16)(p13.1;q22) +7	Fred Hutchinson Cancer Center	Completed	No outcome recorded

Phase 1/252 trials
Phase 1/2	NCT06557174 Comparator	Oct 2024 → Nov 2025 overdue	neuromyelitis optica	ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT06279494 Background	Mar → Jun 2024	acute leukemia, aplastic anemia, myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 1/2	NCT05807932 Background	Jun 2023 → Jan 2026 overdue	acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome	Heinrich-Heine University, Duesseldorf	Recruiting	No outcome recorded
Phase 1/2	NCT05436418 Background	Nov 2022 → Jun 2027 expected	disease related to hematopoietic stem cell transplant	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT05327023 Background	May 2022 → Jul 2028 expected	hematopoietic and lymphoid cell neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT04959175 Background	Sep 2021 → Apr 2027 expected	hematopoietic and lymphoid cell neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT04083183 Background	Jun 2020 → Jan 2028 expected	benign neoplasm	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT04022239 Background	Mar 2020 → Jul 2027 expected	hematopoietic and lymphoid system neoplasm	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT03842696 Background	Feb 2020 → Jul 2025 overdue	acute leukemia, diffuse large B-cell lymphoma, follicular lymphoma, graft versus host disease +3	University of Michigan Rogel Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT04066114 Background	Dec 2019 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT03670966 Background	Jul 2019 → Jan 2028 expected	acute lymphoblastic leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome with excess blasts	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT03128034 Background	Oct 2017 → Jun 2027 expected	acute lymphoblastic leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome with excess blasts	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT03192397 Background	Aug 2017 → Aug 2023 overdue	Hodgkins lymphoma, Philadelphia-positive myelogenous leukemia, Waldenstrom macroglobulinemia, acute myeloid leukemia +6	Roswell Park Cancer Institute	Active not recruiting	No outcome recorded
Phase 1/2	NCT03247088 Background	Jul 2017 → Dec 2027 expected	acute myeloid leukemia	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT03128996 Background	Mar 2017 → Apr 2028 expected	bone marrow failure syndrome, metabolic disease, sickle cell disease	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT02711826 Background	Sep 2016 → Aug 2023	—	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT02080195 Background	Sep 2016 → Mar 2017	graft versus host disease, lupus erythematosus	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 1/2	NCT02821026 Background	May 2016 → Nov 2019	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT02217410 Background	Feb 2015 → Nov 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT01904136 Background	Apr 2014 → Feb 2022	blast phase chronic myelogenous leukemia, BCR-ABL1 positive, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT02053545 Background	Dec 2013 → May 2017	leukemia, lymphoma, myelodysplastic syndrome	Ann & Robert H Lurie Children's Hospital of Chicago	Withdrawn	No outcome recorded
Phase 1/2	NCT01983761 Background	Nov 2013 → Mar 2014	Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1	Targazyme, Inc.	Unknown	No outcome recorded
Phase 1/2	NCT01701986 Background	Oct 2012 → Jun 2024	B-cell non-Hodgkin lymphoma, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, disease related to hematopoietic stem cell transplant	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT01509300 Background	Jan 2012 → Dec 2013	acute leukemia, cancer, myelodysplastic syndrome	Asan Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT01446484 Background	Oct 2011 → Nov 2014	end stage renal failure, kidney failure	Pirogov Russian National Research Medical University	Unknown	No outcome recorded
Phase 1/2	NCT01379209 Background	Sep 2011 → Jun 2015	graft versus host disease	Regimmune Corporation	Completed	No outcome recorded
Phase 1/2	NCT01203722 Comparator	Sep 2010 → May 2024	hematopoietic and lymphoid system neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1/2	NCT01154387 Background	Jul 2010 → Jun 2013	end stage renal failure	Tolera Therapeutics, Inc	Unknown	No outcome recorded
Phase 1/2	NCT02435901 Background	Dec 2008 → Mar 2019	beta-thalassemia major, sickle cell disease	Northwell Health	Completed	No outcome recorded
Phase 1/2	NCT00789776 Background	Oct 2008 → May 2017	Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +5	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00816413 Background	Sep 2008 → Feb 2010	benign neoplasm, leukemia, lymphoma, myelodysplastic syndrome +1	University of Nebraska	Withdrawn	No outcome recorded
Phase 1/2	NCT00752479 Background	May 2008 → Jul 2013	—	Mario Negri Institute for Pharmacological Research	Terminated	No outcome recorded
Phase 1/2	NCT00423514 Background	Nov 2006 → Jun 2021	graft versus host disease, leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00594932 Comparator	Nov 2006 → Jul 2008	arthritic joint disease, systemic lupus erythematosus	Oklahoma Medical Research Foundation	Completed	No outcome recorded
Phase 1/2	NCT01062555 Comparator	Oct 2006 → Apr 2014	—	University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT01346085 Background	Oct 2006 → Jun 2009	type 1 diabetes mellitus	Ospedale San Raffaele	Completed	No outcome recorded
Phase 1/2	NCT00798785 Background	Oct 2006 → Dec 2014	type 1 diabetes mellitus	University Hospital Brussels	Unknown	No outcome recorded
Phase 1/2	NCT00429143 Background	Jan 2006 → Aug 2009	hematopoietic and lymphoid cell neoplasm	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Completed	No outcome recorded
Phase 1/2	NCT00579527 Background	Dec 2005 → Dec 2011	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 1/2	NCT00245037 Background	Jun 2005 → Aug 2015	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, plasma cell neoplasm +1	OHSU Knight Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT00183248 Background	Sep 2004 → Nov 2009	kidney failure	University of Miami	Completed	No outcome recorded
Phase 1/2	NCT00141037 Background	Mar 2004 → Sep 2006	kidney disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00054353 Background	Oct 2002 → Oct 2009	plasma cell myeloma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00027547 Background	Jul 2001 → Jul 2004	leukemia	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00281983 Background	Jun 2000 → Jul 2010	B-cell chronic lymphocytic leukemia	German CLL Study Group	Completed	No outcome recorded
Phase 1/2	NCT00365287 Background	Jun 2000 → Dec 2005	breast cancer, kidney cancer, leukemia, myelodysplastic syndrome +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00006251 Background	May 2000 → Sep 2005	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +32	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00630253 Background	Feb 2000 → Oct 2020	Fanconi anemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00005851 Background	Feb 2000 → Jul 2004	renal cell carcinoma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00004485 Background	Dec 1999 → Aug 2007	sickle cell disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00005803 Background	Sep 1999 → Jan 2016	Hodgkins lymphoma, T-cell prolymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00003954 Background	Mar 1999 → Dec 2002	plasma cell myeloma	Fred Hutchinson Cancer Center	Completed	No outcome recorded

Phase 2255 trials
Phase 2	NCT07634536 Background	Aug 2026 → Aug 2028 expected	acute myeloid leukemia, myelodysplastic syndrome	Stanford University	Not yet recruiting	No outcome recorded
Phase 2	NCT07524530 Background	Jul 2026 → Jun 2033 expected	core binding factor acute myeloid leukemia, lymphoma	National Cancer Institute (NCI)	Not yet recruiting	No outcome recorded
Phase 2	NCT07619898 Comparator	Jul 2026 → Dec 2028 expected	colitis, hepatitis, melanoma	Therakos	Not yet recruiting	No outcome recorded
Phase 2	NCT07349771 Background	Jun 2026 → Jun 2028 expected	hematopoietic and lymphoid system neoplasm	Mayo Clinic	Not yet recruiting	No outcome recorded
Phase 2	NCT07562568 Background	Jun 2026 → Jun 2030 expected	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	The First Affiliated Hospital of Soochow University	Not yet recruiting	No outcome recorded
Show all 255 trials opens the full record — a long page
Phase 2/314 trials
Phase 2/3	NCT07412470 Background	Mar 2026 → Aug 2029 expected	transplant rejection	Sanofi	Recruiting	No outcome recorded
Phase 2/3	NCT03605654 Background	Dec 2024 → Sep 2026	transplant rejection	Medeor Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 2/3	NCT06650124 Comparator	Nov 2024 → Dec 2025 overdue	autoimmune hepatitis	Institute of Liver and Biliary Sciences, India	Not yet recruiting	No outcome recorded
Phase 2/3	NCT04147390 Comparator	Nov 2019 → Mar 2020	keratopathy	Shahid Beheshti University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT04168944 Background	Nov 2019 → Sep 2022	hepatocellular carcinoma	RenJi Hospital	Unknown	No outcome recorded
Phase 2/3	NCT05063513 Background	Jul 2009 → Jul 2013	systemic lupus erythematosus	European Society for Blood and Marrow Transplantation	Withdrawn	No outcome recorded
Phase 2/3	NCT02707393 Background	Apr 2009 → Dec 2020	chronic myeloid leukemia	St. Anna Children's Cancer Research	Completed	No outcome recorded
Phase 2/3	NCT00891306 Background	Feb 2009 → Aug 2010	familial lipoprotein lipase deficiency	Amsterdam Molecular Therapeutics	Completed	No outcome recorded
Phase 2/3	NCT00573157 Background	Dec 2007 → Apr 2009	lupus nephritis	EMD Serono	Terminated	No outcome recorded
Phase 2/3	NCT01109498 Background	Aug 2007 → Jun 2013	familial lipoprotein lipase deficiency	Amsterdam Molecular Therapeutics	Unknown	No outcome recorded
Phase 2/3	NCT00430677 Background	Jun 2007 → Sep 2010	systemic lupus erythematosus	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 2/3	NCT00352976 Background	May 2006 → Oct 2020	Fanconi anemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00533624 Comparator	Dec 2004 → Feb 2006	end stage renal failure	University of Miami	Completed	No outcome recorded
Phase 2/3	NCT00729768 Background	—	—	Genentech, Inc.	Withdrawn	No outcome recorded

Phase 374 trials
Phase 3	NCT06821542 Background	Jun 2025 → May 2028 expected	chronic graft versus host disease	Incyte Corporation	Active not recruiting	No outcome recorded
Phase 3	NCT06615050 Comparator	Apr 2025 → Jan 2031 expected	graft versus host disease	Incyte Corporation	Recruiting	No outcome recorded
Phase 3	NCT06682169 Comparator	Nov 2024 → Oct 2029 expected	chronic graft versus host disease	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT06258915 Comparator	Mar 2024 → Jun 2027 expected	uveitis	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT05863936 Background	Apr 2023 → Mar 2024	lupus nephritis	Nanjing University School of Medicine	Unknown	No outcome recorded
Phase 3	NCT05627557 Comparator	Mar 2023 → Sep 2025 overdue	idiopathic nephrotic syndrome	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 3	NCT05457556 Background	Mar 2023 → Jun 2026 overdue	acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome	Children's Oncology Group	Active not recruiting	No outcome recorded
Phase 3	NCT04702256 Comparator	Dec 2021 → Dec 2031 expected	lupus nephritis, systemic lupus erythematosus	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05057481 Comparator	Sep 2021 → Dec 2022	autoimmune hemolytic anemia, systemic lupus erythematosus	Assiut University	Unknown	No outcome recorded
Phase 3	NCT04629833 Comparator	Aug 2021 → Aug 2027 expected	acute graft versus host disease	medac GmbH	Recruiting	No outcome recorded
Phase 3	NCT04877288 Background	Jul 2021 → Dec 2032 expected	—	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 3	NCT04660539 Background	Mar 2021 → May 2024	neuromyelitis optica	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT04547049 Comparator	Sep 2020 → Apr 2026 overdue	leukemia, myelodysplastic syndrome	First Affiliated Hospital of Zhejiang University	Active not recruiting	No outcome recorded
Phase 3	NCT04221477 Background	Aug 2020 → Aug 2024 overdue	lupus nephritis	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 3	NCT03828019 Comparator	Sep 2019 → Apr 2024	uveitis	JHSPH Center for Clinical Trials	Completed	No outcome recorded
Phase 3	NCT03899103 Comparator	May 2019 → Sep 2023	idiopathic nephrotic syndrome	Nilratan Sircar Medical College	Completed	No outcome recorded
Phase 3	NCT03480360 Background	Mar 2018 → Feb 2025	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome +2	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 3	NCT03323476 Comparator	Feb 2018 → Mar 2028 expected	anti-neutrophil cytoplasmic antibody-associated vasculitis, end stage renal failure	Centre Hospitalier Departemental Vendee	Active not recruiting	No outcome recorded
Phase 3	NCT03386539 Comparator	Jan 2018 → Apr 2023 overdue	chronic kidney disease, disease related to solid organ transplantation, immunodeficiency disease, post-transplant lymphoproliferative disease +1	Boston Children's Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT03112603 Comparator	Jun 2017 → May 2020	chronic graft versus host disease	Incyte Corporation	Completed	No outcome recorded
Phase 3	NCT02913261 Comparator	Mar 2017 → Jun 2019	acute graft versus host disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02990286 Background	Jan 2017 → Jul 2019	interstitial lung disease	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT02649504 Comparator	Dec 2016	autoimmune thrombocytopenia	Weill Medical College of Cornell University	Withdrawn	No outcome recorded
Phase 3	NCT02909335 Background	Nov 2016 → Nov 2021	—	Rennes University Hospital	Withdrawn	No outcome recorded
Phase 3	NCT02630628 Comparator	Dec 2015 → Dec 2024	lupus nephritis	The University of Hong Kong	Completed	No outcome recorded
Phase 3	NCT02383589 Comparator	May 2015 → Nov 2018	pemphigus vulgaris	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT01773616 Background	Apr 2015 → Dec 2017	lupus nephritis	Imperial College London	Terminated	No outcome recorded
Phase 3	NCT02390362 Comparator	Jan 2015 → Dec 2016	nephrotic syndrome	Nationwide Children's Hospital	Terminated	No outcome recorded
Phase 3	NCT02187900 Comparator	Jun 2014 → Aug 2015	IgA glomerulonephritis	Second Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 3	NCT02028884 Background	Feb 2014 → Jun 2018	neuromyelitis optica	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT01921218 Background	Aug 2013 → Dec 2019	—	Andrew B Adams	Completed	No outcome recorded
Phase 3	NCT01714817 Background	Jan 2013 → Nov 2016	lupus nephritis	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 3	NCT01843348 Comparator	Dec 2012 → Mar 2016	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01544491 Comparator	Aug 2012 → Oct 2016	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01766375 Background	Aug 2012 → Jan 2016	acute myeloid leukemia	Guangxi Medical University	Unknown	No outcome recorded
Phase 3	NCT01595984 Background	May 2012 → Mar 2024	kidney failure	Centre Hospitalier Universitaire, Amiens	Completed	No outcome recorded
Phase 3	NCT01284725 Comparator	Feb 2011 → Feb 2016	lupus nephritis	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 3	NCT01231412 Background	Nov 2010 → Oct 2016	Hodgkins lymphoma, T-cell leukemia, Waldenstrom macroglobulinemia, acute myeloid leukemia +7	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 3	NCT01232920 Comparator	Oct 2010 → Jun 2012	uveitis	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT01025817 Comparator	Jan 2010 → Mar 2013	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01011205 Background	Sep 2009 → Jan 2013	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00933231 Background	Aug 2009 → May 2015	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT01028092 Comparator	Mar 2009 → Mar 2014	—	University Hospital, Brest	Completed	No outcome recorded
Phase 3	NCT01288131 Comparator	Jan 2009 → Jan 2012	pure red-cell aplasia	Chulalongkorn University	Terminated	No outcome recorded
Phase 3	NCT00707759 Background	Jun 2008 → Dec 2012	kidney disorder	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile	Completed	No outcome recorded
Phase 3	NCT00626197 Background	Feb 2008 → Oct 2009	lupus nephritis, systemic lupus erythematosus	Genentech, Inc.	Terminated	No outcome recorded
Phase 3	NCT00658320 Comparator	Feb 2008 → Aug 2010	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00539838 Background	Dec 2007 → Jul 2011	systemic lupus erythematosus	Genentech, Inc.	Terminated	No outcome recorded
Phase 3	NCT00657059 Comparator	Sep 2007 → May 2019	IgA glomerulonephritis	Sun Yat-sen University	Completed	No outcome recorded
Phase 3	NCT00568633 Background	Aug 2007 → Dec 2015	acute myeloid leukemia	Stanford University	Terminated	No outcome recorded
Phase 3	NCT00481819 Background	Jul 2007 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00451867 Comparator	Mar 2007 → Feb 2008	interstitial cystitis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	No outcome recorded
Phase 3	NCT00275509 Background	Jan 2007 → Jun 2010	chronic renal failure syndrome	Johns Hopkins University	Completed	No outcome recorded
Phase 3	NCT00412360 Background	Dec 2006 → Mar 2014	T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1	Medical College of Wisconsin	Completed	No outcome recorded
Phase 3	NCT02005562 Comparator	May 2006 → Mar 2009	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00311311 Background	Apr 2006 → Dec 2010	atherosclerosis, kidney failure	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00334672 Background	Mar 2006 → Nov 2010	—	Children's Cancer and Leukaemia Group	Unknown	No outcome recorded
Phase 3	NCT00282347 Background	Jan 2006 → Jan 2009	lupus nephritis	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00300274 Comparator	Jan 2006 → Jul 2011	transplant rejection	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00322101 Background	Jan 2006 → Apr 2012	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32) +6	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00296348 Background	Nov 2005 → Feb 2008	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00402532 Comparator	Mar 2005 → Nov 2011	—	Hannover Medical School	Completed	No outcome recorded
Phase 3	NCT00135811 Comparator	Nov 2004 → Oct 2009	focal segmental glomerulosclerosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00195273 Background	Nov 2004 → Jul 2008	graft versus host disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT02686619 Background	Nov 2004 → Jan 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00157014 Background	May 2004 → Jul 2008	heart disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT02461121 Comparator	May 2004 → May 2013	acute myeloid leukemia	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Completed	No outcome recorded
Phase 3	NCT00089141 Comparator	May 2004 → Jul 2008	cancer	Martin, Paul	Terminated	No outcome recorded
Phase 3	NCT00075478 Background	Oct 2003 → Feb 2014	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia +5	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00469131 Comparator	Sep 2003 → Aug 2010	cirrhosis of liver, hepatitis C virus infection	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Completed	No outcome recorded
Phase 3	NCT00064701 Background	Jun 2003 → Mar 2005	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00318474 Comparator	Jan 2002 → Mar 2008	IgA glomerulonephritis	St. Joseph's Hospital and Medical Center, Phoenix	Terminated	No outcome recorded
Phase 3	NCT00228020 Background	May 2001 → Jan 2006	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00048152 Background	Dec 2000 → Mar 2006	—	Hoffmann-La Roche	Completed	No outcome recorded

Phase 489 trials
Phase 4	NCT07611214 Background	Apr 2026 → Mar 2029 expected	lupus nephritis	Aurinia Pharmaceuticals Inc.	Recruiting	No outcome recorded
Phase 4	NCT06942156 Comparator	Aug 2025 → Dec 2030 expected	—	Chong Kun Dang Pharmaceutical	Not yet recruiting	No outcome recorded
Phase 4	NCT06568549 Comparator	Jun 2025 → Dec 2030 expected	—	Mayo Clinic	Recruiting	No outcome recorded
Phase 4	NCT06044493 Comparator	Nov 2023 → Oct 2025	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 4	NCT06178146 Background	Sep 2023 → Nov 2024	—	Jun Wang	Unknown	No outcome recorded
Phase 4	NCT06114953 Comparator	Jan 2023 → Jan 2025	disease related to solid organ transplantation	Lee's Pharmaceutical Limited	Unknown	No outcome recorded
Phase 4	NCT05666336 Background	Dec 2022 → Jun 2024	systemic lupus erythematosus	Fen Li	Unknown	No outcome recorded
Phase 4	NCT04773392 Comparator	Nov 2021 → Feb 2024	transplant rejection	University of Southern California	Terminated	No outcome recorded
Phase 4	NCT05193565 Comparator	Nov 2021 → Jul 2026 overdue	—	Chong Kun Dang Pharmaceutical	Active not recruiting	No outcome recorded
Phase 4	NCT04936971 Comparator	Sep 2021	cytomegalovirus infection	Edoardo Melilli	Withdrawn	No outcome recorded
Phase 4	NCT04376528 Comparator	Jun → Dec 2021	autoimmune hepatitis, primary biliary cholangitis	West China Hospital	Unknown	No outcome recorded
Phase 4	NCT04849533 Comparator	Apr 2021 → Jul 2023	transplant rejection	University of Cincinnati	Unknown	No outcome recorded
Phase 4	NCT05303272 Comparator	Feb 2021 → Sep 2022	pemphigus vulgaris	Tongji Hospital	Unknown	No outcome recorded
Phase 4	NCT04700709 Comparator	Jan 2021 → Dec 2024	—	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 4	NCT04471441 Comparator	Jun 2020 → Jul 2024	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 4	NCT04048161 Comparator	Nov 2019 → May 2023	nephrotic syndrome	The Children's Hospital of Zhejiang University School of Medicine	Completed	No outcome recorded
Phase 4	NCT04207177 Comparator	Oct 2019 → Dec 2025	immune system disorder	Oslo University Hospital	Unknown	No outcome recorded
Phase 4	NCT04203108 Background	Sep 2019 → Aug 2021	—	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT03920059 Comparator	Aug 2019 → Jan 2020	lupus nephritis	Chulalongkorn University	Terminated	No outcome recorded
Phase 4	NCT03797196 Comparator	Jul 2019 → Jun 2025 overdue	disease related to solid organ transplantation	University Medical Center Groningen	Active not recruiting	No outcome recorded
Phase 4	NCT04009525 Background	Jul 2019 → Jul 2023	beta-thalassemia major	First Affiliated Hospital of Guangxi Medical University	Completed	No outcome recorded
Phase 4	NCT03828682 Background	Jun 2019 → Jul 2021	immunodeficiency disease	Simon Tremblay, PharmD, PhD	Unknown	No outcome recorded
Phase 4	NCT03315052 Background	Jan 2019 → Jan 2021	acute transplant rejection	Montefiore Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT03689465 Comparator	Oct 2018 → Sep 2020	disease related to hematopoietic stem cell transplant	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT03099122 Background	Aug 2017 → Nov 2019	end stage renal failure	Sanofi	Completed	No outcome recorded
Phase 4	NCT02953873 Background	May 2017 → Sep 2018	immunodeficiency disease	Medical University of South Carolina	Completed	No outcome recorded
Phase 4	NCT03171831 Background	Apr 2017 → Dec 2021	beta-thalassemia major	First Affiliated Hospital of Guangxi Medical University	Unknown	No outcome recorded
Phase 4	NCT03415750 Comparator	Nov 2016 → May 2020	—	Edoardo Melilli	Completed	No outcome recorded
Phase 4	NCT02864706 Comparator	Jan 2016 → Sep 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02677181 Background	Jan 2016 → Jan 2020	acute graft versus host disease	Chinese PLA General Hospital	Completed	No outcome recorded
Phase 4	NCT02498977 Comparator	Oct 2015 → Dec 2021	liver disorder	King's College London	Terminated	No outcome recorded
Phase 4	NCT02342145 Background	Apr 2015 → Aug 2022	beta-thalassemia major, graft versus host disease	Zhongming Zhang	Completed	No outcome recorded
Phase 4	NCT02226341 Comparator	Oct 2014 → Jan 2024	lupus nephritis	Columbia University	Terminated	No outcome recorded
Phase 4	NCT02077556 Comparator	Apr 2014 → Jan 2019	—	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT02081755 Comparator	Mar 2014 → Mar 2027 expected	hepatocellular carcinoma	Baylor Research Institute	Enrolling by invitation	No outcome recorded
Phase 4	NCT02058875 Comparator	Feb 2014 → Oct 2015	cardiovascular disorder, disease related to solid organ transplantation	University of Saskatchewan	Withdrawn	No outcome recorded
Phase 4	NCT01950819 Comparator	Dec 2013 → Feb 2017	end stage renal failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01822483 Comparator	Apr 2013 → Mar 2015	—	Irmandade Santa Casa de Misericórdia de Porto Alegre	Completed	No outcome recorded
Phase 4	NCT01729494 Background	Sep 2012 → Dec 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT01742624 Background	Apr → Jun 2012	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT01435291 Background	Oct 2011 → May 2013	—	Centre Hospitalier Universitaire de Nice	Completed	No outcome recorded
Phase 4	NCT01304836 Background	Jan 2011 → May 2013	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT01095172 Background	Nov 2010 → Oct 2020	—	Guy's and St Thomas' NHS Foundation Trust	Unknown	No outcome recorded
Phase 4	NCT01002339 Background	Feb 2010 → Feb 2014	type 2 diabetes mellitus	Armando Torres Ramírez	Terminated	No outcome recorded
Phase 4	NCT01266148 Background	Nov 2009 → Dec 2012	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00975663 Comparator	Sep 2009 → Feb 2011	—	University Hospital, Limoges	Terminated	No outcome recorded
Phase 4	NCT01017029 Background	Sep 2009 → Dec 2013	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00843856 Comparator	Mar 2009 → Mar 2018	membranous glomerulonephritis	Imperial College Healthcare NHS Trust	Completed	No outcome recorded
Phase 4	NCT00817687 Comparator	Jan 2009 → Jan 2012	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00737659 Comparator	Aug 2008 → Aug 2011	—	Rabin Medical Center	Unknown	No outcome recorded
Phase 4	NCT00724022 Background	Jun 2008 → Jul 2014	disease related to solid organ transplantation	University Hospital Freiburg	Completed	No outcome recorded
Phase 4	NCT00717470 Comparator	May 2008 → Mar 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT01195194 Background	Mar 2008 → Jun 2012	disease related to solid organ transplantation	Josep M Grinyo	Completed	No outcome recorded
Phase 4	NCT00658333 Comparator	Mar 2008 → Mar 2009	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT00611494 Comparator	Jan 2008 → Dec 2009	disease related to solid organ transplantation	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00717379 Background	May 2007 → Oct 2008	chronic renal failure syndrome	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00522548 Comparator	Mar 2007 → Jan 2011	—	University of Pennsylvania	Terminated	No outcome recorded
Phase 4	NCT00400400 Comparator	Oct 2006 → Jun 2008	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00420537 Comparator	Sep 2006 → Jan 2009	impaired renal function disease	University of Bologna	Terminated	No outcome recorded
Phase 4	NCT00400647 Comparator	Jul 2006 → Sep 2008	—	Novartis	Completed	No outcome recorded
Phase 4	NCT01101802 Comparator	Mar 2006 → Mar 2008	atherosclerosis, systemic lupus erythematosus	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT00695344 Comparator	Jan 2006 → Jun 2010	—	Fundacion Investigacion y Desarrollo	Unknown	No outcome recorded
Phase 4	NCT00169910 Comparator	Dec 2005 → Dec 2010	cardiovascular disorder	Leiden University Medical Center	Completed	No outcome recorded
Phase 4	NCT00596947 Comparator	Oct 2005 → Mar 2009	—	University of Pennsylvania	Terminated	No outcome recorded
Phase 4	NCT00121784 Background	Oct 2005 → Aug 2006	—	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 4	NCT00239005 Comparator	Sep 2005 → Mar 2008	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00132691 Comparator	Sep 2005 → Dec 2010	uveitis	JHSPH Center for Clinical Trials	Completed	No outcome recorded
Phase 4	NCT00371319 Comparator	Sep 2005 → May 2014	lupus nephritis	Tuen Mun Hospital	Completed	No outcome recorded
Phase 4	NCT00118742 Background	Aug 2005 → Jul 2008	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00133172 Background	Jul 2005 → Mar 2007	—	Astellas Pharma Inc	Terminated	No outcome recorded
Phase 4	NCT00307671 Background	Jul 2005 → Jul 2011	eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, polyarteritis nodosa	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT00113269 Background	May 2005 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00166712 Comparator	Apr 2005 → Apr 2010	chronic transplant rejection	Northwestern University	Terminated	No outcome recorded
Phase 4	NCT00374647 Background	Mar 2005 → Dec 2007	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00160966 Comparator	Sep 2004 → Mar 2010	polyomavirus infectious disease	University of Giessen	Completed	No outcome recorded
Phase 4	NCT00166829 Background	May 2004 → ?	—	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT00299221 Comparator	Apr 2004 → Jun 2009	immunodeficiency disease	Newark Beth Israel Medical Center	Completed	No outcome recorded
Phase 4	NCT02554955 Background	Feb 2004 → Dec 2007	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT03582878 Comparator	Jan 2004 → Jan 2019	type 1 diabetes mellitus	Institute for Clinical and Experimental Medicine	Completed	No outcome recorded
Phase 4	NCT00121810 Background	Aug 2003 → Nov 2009	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00166244 Comparator	May 2003 → Mar 2005	—	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT00374231 Background	Oct 2002 → Jan 2008	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00275535 Comparator	Apr 2001 → Nov 2007	kidney disorder	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT00200551 Background	Jan 2001 → Apr 2010	—	Nantes University Hospital	Completed	No outcome recorded
Phase 4	NCT00812123 Background	Jan 2001 → Jul 2005	chronic kidney disease	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT00650468 Background	Nov 1999 → Dec 2007	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT00048165 Background	Aug 1999 → Aug 2002	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00687180 Comparator	—	autoimmune hepatitis	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 4	NCT00261820 Background	? → Jan 2005	kidney failure, transplant rejection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Phase not applicable39 trials
—	NCT06310837 Background	Mar 2024 → Oct 2025 overdue	uveitis	Zhongshan Ophthalmic Center, Sun Yat-sen University	Active not recruiting	No outcome recorded
—	NCT05974683 Comparator	Aug 2023 → Dec 2025	autoimmune disease	Peking Union Medical College Hospital	Unknown	No outcome recorded
—	NCT04838704 Comparator	Apr 2021 → Dec 2024	graft versus host disease	Zhejiang University	Completed	No outcome recorded
—	NCT04906304 Background	Jan → Jul 2020	cytomegalovirus infection	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
—	NCT03412188 Comparator	Aug 2018 → Sep 2021	autoimmune thrombocytopenic purpura	Nayera Hazaa Elsherif	Completed	No outcome recorded
—	NCT03492255 Background	Apr 2018 → Jul 2021	systemic lupus erythematosus	University of Sao Paulo General Hospital	Terminated	No outcome recorded
—	NCT03035422 Background	Jan 2018 → Dec 2021	acute myeloid leukemia	Association for Training, Education, and Research in Hematology, Immunology, and Transplantation	Completed	No outcome recorded
—	NCT03079089 Background	Jun 2017 → Sep 2023	lymphoid hemopathy	Association for Training, Education, and Research in Hematology, Immunology, and Transplantation	Completed	No outcome recorded
—	NCT02954939 Comparator	Mar 2017 → Dec 2028 expected	lupus nephritis	The University of Hong Kong	Recruiting	No outcome recorded
—	NCT02954198 Comparator	Dec 2016 → Dec 2018	immunodeficiency disease	Medical University of South Carolina	Completed	No outcome recorded
—	NCT01962636 Background	Dec 2016 → May 2026	Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +11	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT02936505 Background	Oct 2016 → Oct 2025 overdue	—	Vastra Gotaland Region	Active not recruiting	No outcome recorded
—	NCT02880293 Background	Aug 2016 → Nov 2023	hematopoietic and lymphoid cell neoplasm	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT02839941 Background	Aug 2016 → Jul 2019	—	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
—	NCT02652468 Background	Mar 2016 → Sep 2018	lymphoma	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT02095418 Comparator	Feb 2014 → Feb 2018	diabetes mellitus	Samsung Medical Center	Unknown	No outcome recorded
—	NCT01850108 Background	May 2013 → Nov 2023	sickle cell disease	Vanderbilt-Ingram Cancer Center	Unknown	No outcome recorded
—	NCT01653847 Comparator	Feb 2013 → May 2020	end stage renal failure	Northwestern University	Completed	No outcome recorded
—	NCT01685411 Background	Jan 2013 → Feb 2020	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01626092 Background	Jul 2012 → Nov 2013	lysosomal storage disease, peroxisomal disease	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00970073 Background	Aug 2009 → Jun 2015	—	The Cleveland Clinic	Completed	No outcome recorded
—	NCT01005706 Comparator	Aug 2009 → Jul 2013	renal agenesis	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00934791 Comparator	Feb 2009 → Dec 2012	autosomal dominant polycystic liver disease	Mayo Clinic	Terminated	No outcome recorded
—	NCT00619528 Background	Jan 2008 → Jul 2022	immunodeficiency disease, transplant rejection	Northwestern University	Completed	No outcome recorded
—	NCT00594308 Background	Oct 2007 → Oct 2008	Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +4	Indiana University	Terminated	No outcome recorded
—	NCT00336817 Comparator	Nov 2006 → Nov 2008	immunodeficiency disease	University of Pittsburgh	Completed	No outcome recorded
—	NCT00298506 Comparator	Sep 2005 → Dec 2008	lupus nephritis	Nanjing University School of Medicine	Completed	No outcome recorded
—	NCT00547196 Background	Aug 2005 → Nov 2009	leukemia, lymphoma, myelodysplastic syndrome	City of Hope Medical Center	Completed	No outcome recorded
—	NCT00295997 Background	May 2005 → ?	kidney cancer, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	University of California, San Francisco	Unknown	No outcome recorded
—	NCT00255684 Background	Dec 2003 → Mar 2013	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	University of Rochester	Terminated	No outcome recorded
—	NCT00301600 Comparator	Jan 2003 → May 2005	IgA glomerulonephritis	Nanjing University School of Medicine	Completed	No outcome recorded
—	NCT00301613 Comparator	Jan 2003 → May 2005	immunoglobulin A vasculitis, nephritis	Nanjing University School of Medicine	Completed	No outcome recorded
—	NCT00214279 Background	May 2002 → Nov 2007	—	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00290641 Background	Apr 2001 → Jan 2006	leukemia, lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00010361 Background	Nov 2000 → Apr 2007	chronic granulomatous disease, inborn errors of metabolism	Fred Hutchinson Cancer Center	Completed	No outcome recorded
—	NCT00005799 Background	Nov 1999 → Jul 2002	Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia, Waldenstrom macroglobulinemia +22	Fred Hutchinson Cancer Center	Completed	No outcome recorded
—	NCT00112593 Background	Nov 1999 → Nov 2014	AIDS-related primary central nervous system lymphoma, Burkitt lymphoma, HIV infectious disease, Hodgkins lymphoma +51	Fred Hutchinson Cancer Center	Completed	No outcome recorded
—	NCT00290628 Background	Oct 1999 → Apr 2007	Diamond-Blackfan anemia, Fanconi anemia, graft versus host disease, leukemia +4	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT00003196 Background	Sep 1997 → Apr 2002	Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, adult T-cell leukemia/lymphoma +19	Fred Hutchinson Cancer Center	Completed	No outcome recorded

Phase not stated2 trials
—	NCT00423826 Background	Jan 2007 → Jan 2015	leukemia, myelodysplastic syndrome, myelofibrosis, plasma cell neoplasm +1	Barbara Ann Karmanos Cancer Institute	No longer available	No outcome recorded
—	NCT01309022 Background	—	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	No longer available	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2019-10-14	Roche Global Development	Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris roche.com ↗

Evidence & citations 27 cited values

Every value below carries the sentence it was read from. 866 sources stand behind the page.

Field	Value	Cited text
Known as	mycophenolate mofetil	“The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗ 795 “The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “Specifically, this study is designed to determine the ability of Mycophenolate Mofetil (MMF/CellCept) used alone, or in combination with Daclizumab (DZB/Zenapax) to see if it...” NCT00100178 ↗ “BACKGROUND: To reduce long-term nephrotoxic calcineurin inhibitor dosage, adjunctive sirolimus or mycophenolate mofetil (MMF) was used in a 150-patient, randomized, three-armed...” PMID 14742989 ↗ Jan 2004 “Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the...” NCT01640743 ↗ “The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years...” NCT00975663 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through...” NCT02579967 ↗ “As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA);...” NCT02028884 ↗ “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours...” NCT00360685 ↗ “In this prospective study, 40 patients with class V+IV lupus nephritis were randomly assigned to induction therapy with mycophenolate mofetil, tacrolimus, and steroids...” PMID 18596121 ↗ Jul 2008 “After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and...” NCT01321112 ↗ “Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched...” NCT00304720 ↗ “Forty type 1 diabetes recipients of intraportal islet cell grafts under antithymocyte globulin induction and mycophenolate mofetil-tacrolimus maintenance immunosuppression were...” PMID 32433237 ↗ Oct 2020 “When a donor organ becomes available for transplant, the patient will receive three anti-rejection drugs-cyclosporine, mycophenolate mofetil and prednisone-to prevent organ rejection.” NCT00009009 ↗ “The aim of this substudy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blood pressure monitoring and carotid intima media thickness.” PMID 23715049 ↗ Jul 2013 “Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake” NCT01195194 ↗ “mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax)” NCT06297096 ↗ “The immunosuppressive regimen after liver transplantation is in most cases based on different combinations of tacrolimus, mycophenolate mofetil and corticosteroids.” NCT06354179 ↗ “The original or standard haplo-HSCT GVHD prophylaxis regimen included PTCy on days +3 and +4, with mycophenolate mofetil (MMF) and tacrolimus starting on day +5.” PMID 38281591 ↗ Jan 2024 “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).” NCT01950819 ↗ “Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)” NCT00001964 ↗ “Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF” NCT01134952 ↗ “They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).” NCT00447265 ↗ “This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on lymphocyte subsets in patients with proliferative lupus nephritis.” NCT02954939 ↗ “Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.” NCT06517641 ↗ “Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.” NCT02426502 ↗ “Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.” NCT02416674 ↗ “an anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.” NCT03644667 ↗ “begin a post-transplant maintenance regimen of tacrolimus and mycophenolate mofetil (MMF), with or without steroids after transplantation.” NCT05423496 ↗ “Patients from the CCTPT-PC01 study have been maintained on sirolimus and mycophenolate mofetil (MMF) since 2-3 months post transplant.” NCT00768729 ↗ “The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the chronic hyperactivation of the immune system” NCT00120419 ↗ “In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.” NCT00145613 ↗ “Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination” NCT05060991 ↗ “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID” NCT00849147 ↗ “in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols” NCT01379209 ↗ “Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid” NCT01680952 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD” NCT03314974 ↗ “Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated” NCT04002115 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “Compared with mycophenolate mofetil (MMF) and dexamethasone, cyclosporin probably makes little or no difference” PMID 40337980 ↗ May 2025 “Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35” NCT01597778 ↗ “Starting on Day 5, you will receive tacrolimus and mycophenolate mofetil (MMF) to help lower the risk of GVHD.” NCT01010217 ↗ “mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later.” NCT02776202 ↗ “prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus” NCT00214279 ↗ “Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus” NCT04168944 ↗ “standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid” NCT04883619 ↗ “Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis” NCT01203709 ↗ “maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.” NCT01275274 ↗ “Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545 ↗ “Mycophenolate mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic)” NCT00611494 ↗ “mycophenolate mofetil (MMF) probably makes little or no difference to graft loss and BK viraemia” PMID 39382091 ↗ Oct 2024 “Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months” NCT01053221 ↗ “Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD)” NCT01582048 ↗ “Tacrolimus (TAC) + Mycophenolate mofetil (MMF) + Corticosteroids (CS) up to End of Study (EOS).” NCT03781414 ↗ “Starting on Day -3, you will receive mycophenolate mofetil as a tablet by mouth 2 times a day.” NCT01983761 ↗ “Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid” NCT06310837 ↗ “Mycophenolate mofetil (MMF) 15 mg/kg PO TID (maximum daily dose of 3g/day) starting on Day 5” NCT04187105 ↗ “Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day)” NCT01203722 ↗ “Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX)” NCT07562568 ↗ “standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids” NCT04221477 ↗ “maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization” NCT05063513 ↗ “mycophenolate mofetil (MMF), to help prevent the body from rejecting the stem cells” NCT00864227 ↗ “Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35” NCT05298358 ↗ “in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention” NCT06926595 ↗ “azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials” NCT04726553 ↗ “standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA)” NCT04376827 ↗ “Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)” NCT03035422 ↗ “treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus” NCT01517984 ↗ “methotrexate, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy)” NCT07570745 ↗ “CELLCEPT (mycophenolate mofetil \[MMF\]) or MYFORTIC (mycophenolic acid \[MPA\])” NCT07611214 ↗ “maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day)” NCT01346085 ↗ “Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)” NCT03079089 ↗ “Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.” NCT01002339 ↗ “continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54)” PMID 32406111 ↗ Jun 2020 “mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis” NCT05436418 ↗ “combined with mycophenolate mofetil, at an initial dosage of 2 grams a day” NCT00538265 ↗ “All received oral tacrolimus, mycophenolate mofetil, and corticosteroids.” PMID 17919618 ↗ Oct 2007 “methotrexate, mycophenolate mofetil or azathioprine for antimetabolites” NCT03828019 ↗ “mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid” NCT00325741 ↗ “Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses.” NCT02991898 ↗ “mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor” NCT02876679 ↗ “Mycophenolate mofetil (MMF) is widely used as an immunosuppressant” PMID 31397274 ↗ Oct 2019 “Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0” NCT01028092 ↗ “Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura” NCT05951517 ↗ “mycophenolate mofetil (MMF) and tacrolimus converted to sirolimus” NCT00619528 ↗ “mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase” PMID 33750034 ↗ May 2021 “Mycophenolate mofetil (NA )Stopped upon sirolimus initiation” NCT04415476 ↗ “Start of tacrolimus \& Start of mycophenolate mofetil (MMF)” NCT03128996 ↗ “Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)” NCT01056237 ↗ “May be cyclosporine, mycophenolate mofetil, or tacrolimus” NCT00135694 ↗ “Other Name: Mycophenolate Mofetil or Mycophenolic Acid” NCT01435291 ↗ “Mycophenolate mofetil (MMF) on days +5 through +25” NCT03922724 ↗ “1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;” NCT05863936 ↗ “or plus mycophenolate mofetil, or methotrexate.” NCT00972660 ↗ “everolimus plus mycophenolate mofetil (MMF)” NCT03596970 ↗ “mycophenolate mofetil (MMF) or equivalent” NCT05077254 ↗ “Mycophenolate mofetil, 250mg/cap, orally” NCT01766518 ↗ “Mycophenolate mofetil (1 g twice daily)” NCT07519005 ↗ “CellCept® (mycophenolate mofetil- MMF)” NCT01436305 ↗ “Mycophenolate Mofetil 1000 mg per day” NCT06254248 ↗ “low dose mycophenolate mofetil (MMF)” PMID 39513526 ↗ Nov 2024 “Mycophenolate mofetil (\<=1.5 g/D)” NCT06155604 ↗ “CellCept (mycophenolate mofetil)” NCT00405860 ↗ “mycophenolate mofetil (Cellcept)” NCT00132691 ↗ “rituximab, Mycophenolate mofetil” NCT03412188 ↗ “mycophenolate mofetil (MMF/MPA)” NCT00604357 ↗ “• Mycophenolate mofetil (MMF)” NCT07124078 ↗ “* Mycophenolate mofetil (MMF)” NCT02988466 ↗ “mycophenolate mofetil (MMF)” PMID 25677074 ↗ Feb 2015 “mycophenolate mofetil (MMF)” PMID 35224732 ↗ Feb 2022 “Mycophenolate Mofetil (MMF)” NCT06279494 ↗ “Drug: Mycophenolate Mofetil” NCT02880293 ↗ “Mycophenolate mofetil dose:” NCT05073822 ↗ “Mycophenolate Mofetil (MMF)” NCT02390362 ↗ “mycophenolate Mofetil(MMF)” NCT04203108 ↗ “MMF, Mycophenolate Mofetil” NCT01062555 ↗ “mycophenolate mofetil” NCT05000216 ↗ “mycophenolate mofetil” NCT06297096 ↗ “Mycophenolate mofetil” NCT00045305 ↗ “mycophenolate mofetil” NCT01653847 ↗ “Mycophenolate mofetil” NCT01056822 ↗ “Mycophenolate Mofetil” NCT06178146 ↗ “mycophenolate mofetil” NCT05000216 ↗ NCT05303272 ↗ NCT00295425 ↗ NCT04959175 ↗ NCT00021489 ↗ NCT07340463 ↗ NCT03674411 ↗ NCT03434730 ↗ NCT03605654 ↗ NCT02487069 ↗ NCT00400400 ↗ NCT00301951 ↗ NCT05622318 ↗ NCT00910663 ↗ NCT02909335 ↗ NCT01413100 ↗ NCT03712878 ↗ NCT04644016 ↗ NCT00105235 ↗ NCT01884571 ↗ NCT00040846 ↗ NCT02077556 ↗ NCT00425802 ↗ NCT00105001 ↗ NCT06288932 ↗ NCT00223301 ↗ NCT02821026 ↗ NCT00891306 ↗ NCT05570409 ↗ NCT01252667 ↗ NCT07162038 ↗ NCT00104858 ↗ NCT01014442 ↗ NCT00411515 ↗ NCT00863252 ↗ NCT05221411 ↗ NCT02217410 ↗ NCT06996119 ↗ NCT01499355 ↗ NCT02181478 ↗ NCT00911274 ↗ NCT00862979 ↗ NCT00303719 ↗ NCT03828682 ↗ NCT06055608 ↗ NCT04262843 ↗ NCT03262441 ↗ NCT00006042 ↗ NCT00035555 ↗ NCT01350245 ↗ NCT00531635 ↗ NCT04744623 ↗ NCT07349771 ↗ NCT01011205 ↗ NCT06068179 ↗ NCT04471441 ↗ NCT01349101 ↗ NCT02441803 ↗ NCT00103792 ↗ NCT05457556 ↗ NCT05666336 ↗ NCT02532777 ↗ NCT00400647 ↗ NCT00752479 ↗ NCT00285350 ↗ NCT04838704 ↗ NCT01251575 ↗ NCT00533442 ↗ NCT00943228 ↗ NCT00824135 ↗ NCT01801280 ↗ NCT00305682 ↗ NCT00533624 ↗ NCT06615050 ↗ NCT01729494 ↗ NCT01685411 ↗ NCT01008462 ↗ NCT07524530 ↗ NCT00534430 ↗ NCT01279616 ↗ NCT01092962 ↗ NCT03112603 ↗ NCT00036738 ↗ NCT01790594 ↗ NCT00261820 ↗ NCT02199041 ↗ NCT01016626 ↗ NCT05736419 ↗ NCT00782379 ↗ NCT01428973 ↗ NCT01093586 ↗ NCT00301652 ↗ NCT00397813 ↗ NCT01017029 ↗ NCT00611351 ↗ NCT04083183 ↗ NCT00301613 ↗ NCT05039619 ↗ NCT07548983 ↗ NCT01005706 ↗ NCT04022239 ↗ NCT00005941 ↗ NCT00185640 ↗ NCT06752694 ↗ NCT02248597 ↗ NCT03386539 ↗ NCT00301600 ↗ NCT07359859 ↗ NCT06375005 ↗ NCT02864706 ↗ NCT00185692 ↗ NCT00005935 ↗ NCT05236036 ↗ NCT00224874 ↗ NCT00045435 ↗ NCT01807611 ↗ NCT01570348 ↗ NCT00412360 ↗ NCT00195988 ↗ NCT00425438 ↗ NCT05237323 ↗ NCT00946023 ↗ NCT00579527 ↗ NCT00817687 ↗ NCT06044493 ↗ NCT02649504 ↗ NCT06365437 ↗ NCT01527045 ↗ NCT02333162 ↗ NCT03492255 ↗ NCT02458196 ↗ NCT00006233 ↗ NCT00307645 ↗ NCT00371319 ↗ NCT00049504 ↗ NCT00307671 ↗ NCT04660539 ↗ NCT06258915 ↗ NCT03192397 ↗ NCT01871441 ↗ NCT00006251 ↗ NCT00085449 ↗ NCT03670966 ↗ NCT01002742 ↗ NCT00717314 ↗ NCT01282073 ↗ NCT03108274 ↗ NCT00763490 ↗ NCT02743247 ↗ NCT00737659 ↗ NCT01951885 ↗ NCT01342289 ↗ NCT02294552 ↗ NCT02080195 ↗ NCT00717379 ↗ NCT01626092 ↗ NCT00060424 ↗ NCT04877288 ↗ NCT01135329 ↗ NCT01434472 ↗ NCT02921789 ↗ NCT00358657 ↗ NCT05113004 ↗ NCT02677181 ↗ NCT00717470 ↗ NCT00195273 ↗ NCT06942156 ↗ NCT04888741 ↗ NCT04232085 ↗ NCT01532635 ↗ NCT00133172 ↗ NCT01529827 ↗ NCT01341301 ↗ NCT00827099 ↗ NCT02461121 ↗ NCT03943147 ↗ NCT03415750 ↗ NCT03794492 ↗ NCT00119392 ↗ NCT00119366 ↗ NCT01954784 ↗ NCT00119340 ↗ NCT02120157 ↗ NCT02220985 ↗ NCT05115630 ↗ NCT02566304 ↗ NCT00309842 ↗ NCT01399047 ↗ NCT01213394 ↗ NCT06412497 ↗ NCT01266148 ↗ NCT01621477 ↗ NCT05843968 ↗ NCT00420472 ↗ NCT00262886 ↗ NCT01284725 ↗ NCT00539838 ↗ NCT00446251 ↗ NCT05031897 ↗ NCT01810588 ↗ NCT00003954 ↗ NCT03292861 ↗ NCT02423915 ↗ NCT00420537 ↗ NCT00446459 ↗ NCT00005851 ↗ NCT00025519 ↗ NCT04810156 ↗ NCT02095418 ↗ NCT03983850 ↗ NCT00683930 ↗ NCT00166829 ↗ NCT02809079 ↗ NCT00683969 ↗ NCT02187900 ↗ NCT00816413 ↗ NCT06493526 ↗ NCT02081183 ↗ NCT07214688 ↗ NCT01175785 ↗ NCT01811368 ↗ NCT00352976 ↗ NCT05207358 ↗ NCT00006350 ↗ NCT01288131 ↗ NCT00005803 ↗ NCT01595984 ↗ NCT05049863 ↗ NCT00997958 ↗ NCT01780844 ↗ NCT00311311 ↗ NCT01392989 ↗ NCT00574496 ↗ NCT00005799 ↗ NCT00166712 ↗ NCT00300274 ↗ NCT02981212 ↗ NCT02782546 ↗ NCT02383589 ↗ NCT05101447 ↗ NCT00626197 ↗ NCT07566377 ↗ NCT05027945 ↗ NCT00118742 ↗ NCT00374231 ↗ NCT00522548 ↗ NCT00118352 ↗ NCT01652014 ↗ NCT02630628 ↗ NCT02630563 ↗ NCT01025817 ↗ NCT00882895 ↗ NCT00374647 ↗ NCT00753103 ↗ NCT00594308 ↗ NCT03088709 ↗ NCT03968588 ↗ NCT00343798 ↗ NCT02678143 ↗ NCT00275509 ↗ NCT07493538 ↗ NCT00275535 ↗ NCT00489281 ↗ NCT00573157 ↗ NCT00934791 ↗ NCT02904772 ↗ NCT03504241 ↗ NCT00228020 ↗ NCT04473911 ↗ NCT02424968 ↗ NCT00134004 ↗ NCT00121784 ↗ NCT00245037 ↗ NCT01714817 ↗ NCT04220008 ↗ NCT04688021 ↗ NCT04473924 ↗ NCT01861106 ↗ NCT00899847 ↗ NCT02221583 ↗ NCT02593123 ↗ NCT02435901 ↗ NCT00113269 ↗ NCT06807606 ↗ NCT00166244 ↗ NCT07675291 ↗ NCT00571662 ↗ NCT01860183 ↗ NCT00160966 ↗ NCT05907746 ↗ NCT02370693 ↗ NCT04384692 ↗ NCT00053014 ↗ NCT03899103 ↗ NCT01701986 ↗ NCT00166153 ↗ NCT02188719 ↗ NCT00543569 ↗ NCT00469131 ↗ NCT00151632 ↗ NCT01028716 ↗ NCT00589316 ↗ NCT00087581 ↗ NCT00544115 ↗ NCT04849533 ↗ NCT00916045 ↗ NCT02723786 ↗ NCT06013423 ↗ NCT00709592 ↗ NCT03170323 ↗ NCT01503242 ↗ NCT02793544 ↗ NCT00121810 ↗ NCT05916781 ↗ NCT00112593 ↗ NCT03032783 ↗ NCT00053196 ↗ NCT03580291 ↗ NCT00959231 ↗ NCT01101802 ↗ NCT02702960 ↗ NCT06114953 ↗ NCT01856257 ↗ NCT03315052 ↗ NCT00357565 ↗ NCT01292226 ↗ NCT03249831 ↗ NCT00365287 ↗ NCT01773616 ↗ NCT00187915 ↗ NCT06799195 ↗ NCT00187941 ↗ NCT01930890 ↗ NCT00468403 ↗ NCT07663422 ↗ NCT04424862 ↗ NCT03920059 ↗ NCT00429143 ↗ NCT06650124 ↗ NCT00494741 ↗ NCT00788567 ↗ NCT05626387 ↗ NCT01711489 ↗ NCT01854814 ↗ NCT02691949 ↗ NCT00193635 ↗ NCT00376519 ↗ NCT01921218 ↗ NCT00545402 ↗ NCT00230035 ↗ NCT00199667 ↗ NCT00007059 ↗ NCT04547049 ↗ NCT05538208 ↗ NCT02498977 ↗ NCT04376528 ↗ NCT04375631 ↗ NCT00789308 ↗ NCT00451867 ↗ NCT05170828 ↗ NCT00566696 ↗ NCT00719849 ↗ NCT00719888 ↗ NCT00243009 ↗ NCT04147390 ↗ NCT06682169 ↗ NCT01471067 ↗ NCT00991510 ↗ NCT00031655 ↗ NCT01220297 ↗ NCT00317785 ↗ NCT00157014 ↗ NCT00686556 ↗ NCT00695344 ↗ NCT04370301 ↗ NCT04927390 ↗ NCT02652468 ↗ NCT00812786 ↗ NCT00183248 ↗ NCT00919503 ↗ NCT03797196 ↗ NCT00337493 ↗ NCT04039373 ↗ NCT02949349 ↗ NCT01822483 ↗ NCT00318474 ↗ NCT04477200 ↗ NCT00141037 ↗ NCT00498316 ↗ NCT06680661 ↗ NCT01742624 ↗ NCT00758602 ↗ NCT00354172 ↗ NCT00282412 ↗ NCT00075478 ↗ NCT00669890 ↗ NCT00189150 ↗ NCT00547196 ↗ NCT01850108 ↗ NCT00282347 ↗ NCT00377637 ↗ NCT00883129 ↗ NCT00044954 ↗ NCT04477629 ↗ NCT03128359 ↗ NCT00729768 ↗ NCT00453388 ↗ NCT00908128 ↗ NCT04207177 ↗ NCT00619645 ↗ NCT00089011 ↗ NCT07412470 ↗ NCT02540395 ↗ NCT00096161 ↗ NCT00027547 ↗ NCT04773392 ↗ NCT00053989 ↗ NCT02029638 ↗ NCT02432339 ↗ NCT00594932 ↗ NCT00789776 ↗ NCT00117689 ↗ NCT05129410 ↗ NCT00096096 ↗ NCT00563589 ↗ NCT00354419 ↗ NCT00240994 ↗ NCT03128034 ↗ NCT06001385 ↗ NCT00038272 ↗ NCT04895423 ↗ NCT00656266 ↗ NCT00200551 ↗ NCT01659606 ↗ NCT01982682 ↗ NCT00707759 ↗ NCT00290628 ↗ NCT00135967 ↗ NCT00089141 ↗ NCT05284942 ↗ NCT00907907 ↗ NCT00876616 ↗ NCT00206076 ↗ NCT00057954 ↗ NCT00003196 ↗ NCT04311632 ↗ NCT02563782 ↗ NCT00693524 ↗ NCT00281983 ↗ NCT04205240 ↗ NCT00812123 ↗ NCT00321113 ↗ NCT01824693 ↗ NCT00008177 ↗ NCT00290641 ↗ NCT00548717 ↗ NCT00387959 ↗ NCT04444843 ↗ NCT05193565 ↗ NCT00423514 ↗ NCT00657059 ↗ NCT00433953 ↗ NCT00054353 ↗ NCT00988715 ↗ NCT07634536 ↗ NCT02861417 ↗ NCT00455013 ↗ NCT00027820 ↗ NCT00970073 ↗ NCT00322101 ↗ NCT02896205 ↗ NCT03247088 ↗ NCT00296348 ↗ NCT00003572 ↗ NCT02548468 ↗ NCT01487577 ↗ NCT02707393 ↗ NCT00404794 ↗ NCT01109498 ↗ NCT00404833 ↗ NCT01269021 ↗ NCT00693381 ↗ NCT00849238 ↗ NCT02075242 ↗ NCT01707004 ↗ NCT02756572 ↗ NCT03121001 ↗ NCT00414128 ↗ NCT00140543 ↗ NCT00255684 ↗ NCT04402580 ↗ NCT02342145 ↗ NCT06789315 ↗ NCT00334672 ↗ NCT04933292 ↗ NCT03388008 ↗ NCT00790439 ↗ NCT04048161 ↗ NCT00255710 ↗ NCT03246906 ↗ NCT03099122 ↗ NCT00658320 ↗ NCT02005562 ↗ NCT06676384 ↗ NCT00239005 ↗ NCT00596947 ↗ NCT00008151 ↗ NCT01946880 ↗ NCT01154387 ↗ NCT01895894 ↗ NCT00456235 ↗ NCT00796068 ↗ NCT03959241 ↗ NCT00658333 ↗ NCT00048165 ↗ NCT00408213 ↗ NCT02990286 ↗ NCT00295997 ↗ NCT00430677 ↗ NCT01300572 ↗ NCT00048152 ↗ NCT05293509 ↗ NCT00136903 ↗ NCT00008307 ↗ NCT00176865 ↗ NCT06872333 ↗ NCT00004485 ↗ NCT05785065 ↗ NCT01446484 ↗ NCT01670565 ↗ NCT00008450 ↗ NCT02550652 ↗ NCT00333437 ↗ NCT01842269 ↗ NCT00618527 ↗ NCT01766375 ↗ NCT00324506 ↗ NCT00482053 ↗ NCT02251821 ↗ NCT01829295 ↗ NCT00093743 ↗ NCT03663335 ↗ NCT04195633 ↗ NCT04066114 ↗ NCT00004567 ↗ NCT05807932 ↗ NCT02554955 ↗ NCT02900443 ↗ NCT00014235 ↗ NCT02918292 ↗ NCT00617604 ↗ NCT02582775 ↗ NCT02091414 ↗ NCT00551291 ↗ NCT03200002 ↗ NCT00433186 ↗ NCT01363752 ↗ NCT04936971 ↗ NCT05789017 ↗ NCT00423826 ↗ NCT04339777 ↗ NCT00281879 ↗ NCT00431119 ↗ NCT01041508 ↗ NCT02556931 ↗ NCT04521946 ↗ NCT00506948 ↗ NCT00352092 ↗ NCT01118013 ↗ NCT04669210 ↗ NCT07619898 ↗ NCT00001764 ↗ NCT05303727 ↗ NCT04700709 ↗ NCT02653196 ↗ NCT02953873 ↗ NCT04531865 ↗ NCT01364987 ↗ NCT04868786 ↗ NCT00795132 ↗ NCT00078858 ↗ NCT06663618 ↗ NCT00214266 ↗ NCT06557174 ↗ NCT02495077 ↗ NCT02954198 ↗ NCT02711826 ↗ NCT01042457 ↗ NCT00148252 ↗ NCT05805605 ↗ NCT05327023 ↗ NCT00556933 ↗ NCT00029380 ↗ NCT02833805 ↗ NCT04530487 ↗ NCT06478017 ↗ NCT02728700 ↗ NCT05306873 ↗ NCT05057481 ↗ NCT07605364 ↗ NCT01043640 ↗ NCT00204230 ↗ NCT04009525 ↗ NCT00023231 ↗ NCT00204022 ↗ NCT01231412 ↗ NCT00110058 ↗ NCT00740467 ↗ NCT01384513 ↗ NCT03096782 ↗ NCT01898377 ↗ NCT00010361 ↗ NCT00843856 ↗ NCT01309022 ↗ NCT02627573 ↗ NCT04942730 ↗ NCT01509300 ↗ NCT01085097 ↗ NCT01044745 ↗ NCT02447055 ↗ NCT00481832 ↗ NCT02839941 ↗ NCT03689465 ↗ NCT02867800 ↗ NCT01580865 ↗ NCT05495893 ↗ NCT00555321 ↗ NCT00481819 ↗ NCT03171831 ↗ NCT06973668 ↗ NCT03221257 ↗ NCT00041288 ↗ NCT02494505 ↗ NCT00723099 ↗ NCT04776850 ↗ NCT01903798 ↗ NCT02446964 ↗ NCT00874315 ↗ NCT05974683 ↗ NCT01304836 ↗ NCT00553098 ↗ NCT04702256 ↗ NCT01047072 ↗ NCT02208037 ↗ NCT00064701 ↗ NCT04903054 ↗ NCT03018223 ↗ NCT01232920 ↗ NCT01904136 ↗ NCT02137239 ↗ NCT01566006 ↗ NCT06859424 ↗ NCT00630253 ↗ NCT06568549 ↗ NCT01690520 ↗ NCT05088356 ↗ NCT03118492 ↗ NCT03426969 ↗ NCT01619761 ↗ NCT00793572 ↗ NCT03582878 ↗ NCT00003145 ↗ NCT03842696 ↗ NCT01760655 ↗ NCT03156452 ↗ NCT04904588 ↗
Known as	CellCept	“In this context, we propose a randomized controlled non-inferiority study to demonstrate that in liver transplant recipients, an immunosuppressive strategy based on single...” NCT06354179 ↗ 58 “Specifically, this study is designed to determine the ability of Mycophenolate Mofetil (MMF/CellCept) used alone, or in combination with Daclizumab (DZB/Zenapax) to see if it...” NCT00100178 ↗ “The objective of this study was to compare the oral availability of a test product of Mycophenolate Mofetil 250 mg capsule to an equivalent oral dose of the commercially...” NCT00910663 ↗ “maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil...” NCT01309022 ↗ “CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver...” NCT00206076 ↗ “The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic...” NCT00333437 ↗ “The drugs that are often used to treat lupus nephritis include prednisone (steroids), cyclophosphamide (Cytoxan), azathioprine (AZA or Imuran), and mycophenolate mofetil (MMF...” NCT00447265 ↗ “The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring.” NCT04444843 ↗ “mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax)” NCT06297096 ↗ “The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept)” NCT00166153 ↗ “Mycophenolate Mofetil (CellCept) is an FDA approved, well tolerated, oral medication used to prevent the body's immune system from attacking transplanted organs.” NCT00997958 ↗ “A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)” NCT00683930 ↗ “A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients” NCT00048152 ↗ “This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days.” NCT01903798 ↗ “1,000 mg mycophenolate mofetil (CellCept® provided by Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany), given twice daily (2 g/d).” NCT00431119 ↗ “MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids” NCT01544491 ↗ “mycophenolate mofetil (CellCept®) and low dose oral prednisolone in patients with moderate to severe Graves' orbitopathy (GO).” PMID 35223896 ↗ Feb 2022 “dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.” NCT03480360 ↗ “Mycophenolate mofetil (CellCept) is used as an immunosuppressive agent in allogenic transplants in pediatric patients” NCT01399047 ↗ “These newer medications include Prograf (tacrolimus), Cellcept (mycophenolate mofetil), and Rapamune (sirolimus).” NCT00352092 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)” NCT00148252 ↗ “We hypothesize that mycophenolate mofetil(Cellcept)is safe and effective for lupus arthritis.” NCT00594932 ↗ “mycophenolate mofetil (mycophenolate mofetil, CellCept, Genentech, N015393/02, 12.08.2009)” NCT05237323 ↗ “immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept” NCT00656266 ↗ “Mycophenolate Mofetil 500 mg Tablets (test) and CellCept® 500 mg Tablets (reference)” NCT00908128 ↗ “maintenance mycophenolate mofetil (CellCept®) and low dose steroids” NCT00849238 ↗ “Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0” NCT01028092 ↗ “Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)” NCT00374647 ↗ “Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)” NCT01050855 ↗ “CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)” NCT00789308 ↗ “mycophenol mofetil (MMF, Cellcept®) 500 mg BID” NCT00120419 ↗ “mycophenolate mofetil [CellCept]” NCT00817687 ↗ “mycophenolate mofetil [CellCept]” NCT00337493 ↗ “Mycophenolate Mofetil (CellCept)” NCT00324506 ↗ “Mycophenolate Mofetil (CellCept)” NCT00433953 ↗ “Mycophenolate Mofetil (cellcept)” NCT00223301 ↗ “mycophenolate mofetil (CellCept)” NCT00683969 ↗ “mycophenolate mofetil (CellCept)” NCT00446459 ↗ “mycophenolate mofetil [CellCept]” NCT00408213 ↗ “mycophenolate mofetil (Cellcept)” NCT00132691 ↗ “mycophenolate mofetil [CellCept]” NCT00121810 ↗ “mycophenolate mofetil [CellCept]” NCT00121784 ↗ “mycophenolate mofetil [CellCept]” NCT00118742 ↗ “mycophenolate mofetil [CellCept]” NCT00420472 ↗ “Cellcept” NCT03670966 ↗ NCT02058875 ↗ NCT03323476 ↗ NCT03480360 ↗ NCT00650468 ↗ NCT02081755 ↗ NCT00933231 ↗ NCT00217152 ↗ NCT00336817 ↗ NCT02226341 ↗ NCT00405860 ↗ NCT04906304 ↗ NCT00461825 ↗ NCT00138970 ↗
Known as	Cellcept for Mycophenolate Mofetil	“Cellcept for Mycophenolate Mofetil” NCT05063513 ↗
Known as	CKD-4101	“CKD-4101 (Mycophenolate Mofetil) Tablet” NCT01016626 ↗
Known as	Decortin H	“Stable dosage of previous treatment with Decortin H®, Leflunomid” NCT02779114 ↗
Known as	Imurel	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03323476 ↗
Known as	MMF	“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ 205 “Specifically, this study is designed to determine the ability of Mycophenolate Mofetil (MMF/CellCept) used alone, or in combination with Daclizumab (DZB/Zenapax) to see if it...” NCT00100178 ↗ “The purpose of this study is to evaluate in lung or heart-lung transplant patients on tacrolimus and mycophenolate the impact of optimized mofetil (MMF) therapeutic drug...” NCT00975663 ↗ “BACKGROUND: To reduce long-term nephrotoxic calcineurin inhibitor dosage, adjunctive sirolimus or mycophenolate mofetil (MMF) was used in a 150-patient, randomized, three-armed...” PMID 14742989 ↗ Jan 2004 “BACKGROUND: We compared protection of mycophenolate mofetil (MMF) and azathioprine (AZA) against acute cellular rejection (ACR) and chronic allograft nephropathy (CAN) in...” PMID 34166370 ↗ Jun 2021 “Although the half-life of mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF) is compatible with once-daily administration, no published randomized...” NCT06354179 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through...” NCT02579967 ↗ “As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA);...” NCT02028884 ↗ “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II...” NCT00245037 ↗ “CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver...” NCT00206076 ↗ “We conducted a double-blind, randomized multicenter trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment...” PMID 19270260 ↗ Mar 2009 “Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes...” NCT05626387 ↗ “Mycophenolate mofetil (MMF), used as adjunct immunosuppression with standard dose PTCy, can have substantial gastrointestinal toxicity and can impede immune reconstitution and...” NCT03983850 ↗ “Starting on Day -3, you will receive mycophenolate mofetil as a tablet by mouth 2 times a day. If you are not able to take the tablet by mouth, you will receive MMF by vein...” NCT01983761 ↗ “We compared 22 LDKT recipients who were administered MZR, tacrolimus, and corticosteroids with a control group (n = 20) treated with mycophenolate mofetil (MMF), tacrolimus,...” PMID 31155174 ↗ Jun 2019 “OBJECTIVE: To report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative...” PMID 25757867 ↗ Mar 2015 “Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis...” NCT05113004 ↗ “MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue...” NCT06680661 ↗ “The drugs that are often used to treat lupus nephritis include prednisone (steroids), cyclophosphamide (Cytoxan), azathioprine (AZA or Imuran), and mycophenolate mofetil (MMF...” NCT00447265 ↗ “MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant.” NCT02540395 ↗ “The aim of this substudy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blood pressure monitoring and carotid intima media thickness.” PMID 23715049 ↗ Jul 2013 “Mycophenolate mofetil (MMF) has surpassed azathioprine as therapy to prevent organ transplant rejection and is sometimes used as an alternative option for autoimmune hepatitis.” NCT02900443 ↗ “Mycophenolate mofetil (MMF) has been shown to be an effective and safe immunosuppressant in the prevention and treatment of rejection after solid organ transplantation.” NCT00563589 ↗ “We compared steady-state pharmacokinetics of mycophenolate mofetil (MMF) - Myfenax(®) (Teva) and CellCept(®) (Roche) - in stable kidney transplant recipients (KTRs).” PMID 22500920 ↗ Apr 2012 “Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.” NCT05039619 ↗ “The original or standard haplo-HSCT GVHD prophylaxis regimen included PTCy on days +3 and +4, with mycophenolate mofetil (MMF) and tacrolimus starting on day +5.” PMID 38281591 ↗ Jan 2024 “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “Scattered research in adults showed that both mycophenolate mofetil (MMF) and cyclophosphamide (CYC) can be used in the induction therapy of lupus nephritis.” NCT05495893 ↗ “Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].” NCT00224874 ↗ “At present, Mycophenolate mofetil (MMF) has been widly used in the treatment of IIM, systemic lupus erythematosus (SLE), ANCA associated vasculitis (AAV).” NCT05129410 ↗ “Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11” NCT02864706 ↗ “Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF).” PMID 9469489 ↗ Feb 1998 “Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.” NCT06517641 ↗ “treatment with enteric-coated mycophenolate sodium (EC-MPS) improves gastrointestinal (GI) tolerability compared with mycophenolate mofetil (MMF).” PMID 21760569 ↗ Aug 2011 “Mycophenolate mofetil (MMF) is a novel immunosuppressive drug with proven efficacy in the treatment of graft rejection in renal transplantation.” NCT00005935 ↗ “Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.” NCT02426502 ↗ “Recently, in a monocentre study mycophenolate mofetil (MMF) was demonstrated to be efficacious and safe in penetrating high-risk keratoplasty.” PMID 15910297 ↗ Jun 2005 “begin a post-transplant maintenance regimen of tacrolimus and mycophenolate mofetil (MMF), with or without steroids after transplantation.” NCT05423496 ↗ “Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients.” NCT00400400 ↗ “Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppressive therapy in pediatric renal and heart transplant recipients.” PMID 21454065 ↗ Mar 2011 “Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen.” NCT06568549 ↗ “The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the chronic hyperactivation of the immune system” NCT00120419 ↗ “Conversion to mycophenolate mofetil (MMF) monotherapy improves renal function, but is related to graft rejection in some recipients.” PMID 28051798 ↗ Jan 2017 “mycophenolic acid(MPA), the active metabolite of mycophenolate mofetil(MMF),could inhibit multifarious effects on endothelial cells” NCT00301613 ↗ “mycophenolate mofetil (MMF) doses increased the proportion of patients reaching therapeutic MPA levels (30 to 60 mg.h/L) by day 5.” PMID 20498245 ↗ May 2010 “Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination” NCT05060991 ↗ “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “The purpose of this study is to learn how safe and well-tolerated mycophenolate mofetil (MMF) is when given with abacavir (ABC).” NCT00021489 ↗ “Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1” NCT00425438 ↗ “* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID” NCT00849147 ↗ “The role of mycophenolate mofetil (MMF) in management of immunoglobulin A nephropathy (IgAN) remains highly controversial.” PMID 36745456 ↗ Feb 2023 “Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.” NCT04773392 ↗ “Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)” NCT05027945 ↗ “The patients who withdrew CsA were given MMF 2 g/d, and CsA troughs were between 75 and 125 ng/mL in MMF withdrawal.” PMID 23351013 ↗ Jan 2013 “maintenance immunosuppressive treatment with low-dose cyclosporine (CsA) plus low-dose mycophenolate mofetil (MMF).” NCT00752479 ↗ “mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter” NCT06650124 ↗ “The role of mycophenolate mofetil (MMF) in the treatment of Graves' orbitopathy (GO) has attracted much attention.” PMID 35959915 ↗ Jun 2022 “relationships between acute allograft rejection and MPA AUC, trough level (C0) or mycophenolate mofetil (MMF) dose” PMID 26192348 ↗ Jul 2015 “mycophenolate mofetil(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).” NCT05843968 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35” NCT01597778 ↗ “Compared with mycophenolate mofetil (MMF) and dexamethasone, cyclosporin probably makes little or no difference” PMID 40337980 ↗ May 2025 “treatment with the immunosuppressive drug mycophenolate mofetil (MMF) to prevent a decrease in kidney function” PMID 18554762 ↗ Jun 2008 “Mycophenolate mofetil (MMF) is immunosuppressive drug used for prevention of rejection after kidney transplant” NCT01860183 ↗ “Patients begin a mycophenolate mofetil (MMF)-containing regimen within the first 5 days after transplantation.” NCT00007059 ↗ “Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months).” NCT06676384 ↗ “mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later.” NCT02776202 ↗ “This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide” NCT00377637 ↗ “concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS)” NCT06365437 ↗ “prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy” NCT02954939 ↗ “efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function” NCT00657059 ↗ “Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.” NCT01085097 ↗ “Patients in the mycophenolate mofetil (MMF) arm will receive MMF for a total of 12 months (if tolerated)” NCT05221411 ↗ “standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid” NCT04883619 ↗ “mycophenolate mofetil (MMF, 1,000 mg/day) treatment of neuromyelitis optica spectrum disorders (NMOSDs)” PMID 30258442 ↗ Sep 2018 “Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis” NCT01203709 ↗ “Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.” NCT01002339 ↗ “conventional treatment with Cyclosporine A (CsA), Mycophenolate mofetil (MMF), and corticosteroids” NCT01266148 ↗ “Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation.” PMID 31561278 ↗ Oct 2019 “Tacrolimus (TAC) + Mycophenolate mofetil (MMF) + Corticosteroids (CS) up to End of Study (EOS).” NCT03781414 ↗ “1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids” NCT02723786 ↗ “Patients receive mycophenolate mofetil (MMF) once on day 3 and then twice daily on days 4-32.” NCT00255710 ↗ “GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28” NCT01428973 ↗ “early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation” NCT07663422 ↗ “This is a research study of an investigational product called Mycophenolate mofetil (MMF).” NCT00433186 ↗ “Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX)” NCT07562568 ↗ “immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept” NCT00656266 ↗ “Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.” NCT05736419 ↗ “whether the addition of mycophenolate mofetil (MMF) to TAC would reduce relapse rate.” PMID 31492152 ↗ Sep 2019 “Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35” NCT05298358 ↗ “Mycophenolate mofetil (MMF) has shown high remission rates in small studies of AAV.” PMID 30612116 ↗ Jan 2019 “Mycophenolate Mofetil (MMF) is an immunosuppressant drug, used to prevent rejection” NCT01566006 ↗ “mycophenolate mofetil (MMF), to help prevent the body from rejecting the stem cells” NCT00864227 ↗ “Mycophenolate mofetil (MMF) is increasingly used to treat primary glomerulopathies.” PMID 16014059 ↗ Aug 2005 “in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention” NCT06926595 ↗ “Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)” NCT01822483 ↗ “basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)” NCT00228020 ↗ “Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)” NCT03035422 ↗ “treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus” NCT01517984 ↗ “either sirolimus or mycophenolate mofetil (MMF) in combination with tacrolimus” PMID 41929991 ↗ Apr 2026 “an investigational formulation of mycophenolate mofetil (MMF) 250 mg capsules” NCT00911274 ↗ “Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)” NCT03079089 ↗ “CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)” NCT06478017 ↗ “mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid” NCT00325741 ↗ “Mycophenolate mofetil (MMF) showed promising results in those patients” NCT05057481 ↗ “Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses.” NCT02991898 ↗ “Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone” NCT00707759 ↗ “mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor” NCT02876679 ↗ “Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.” NCT02432339 ↗ “in combination with mycophenolate mofetil (MMF) and corticosteroids.” NCT00573157 ↗ “Advagraf® and Mycophenolate Mofetil (MMF) immunosuppressive regimen” NCT01363752 ↗ “including mycophenolate mofetil (MMF group) during the same period.” PMID 19670189 ↗ Jun 2009 “treated with both mycophenolate mofetil (MMF) and tacrolimus (Tac)” NCT04207177 ↗ “Mycophenolate mofetil (MMF) is widely used as an immunosuppressant” PMID 31397274 ↗ Oct 2019 “mycophenolate mofetil (MMF) and tacrolimus converted to sirolimus” NCT00619528 ↗ “oral mycophenolate mofetil (MMF) once every 12 hours on days 1-40” NCT00619645 ↗ “mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase” PMID 33750034 ↗ May 2021 “Mycophenolate mofetil (MMF) as one of the first-step therapies” PMID 37230499 ↗ Jun 2023 “Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)” NCT00374647 ↗ “Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)” NCT01050855 ↗ “with the immunosuppressant drug mycophenolate mofetil (MMF)” NCT01101802 ↗ “Start of tacrolimus \& Start of mycophenolate mofetil (MMF)” NCT03128996 ↗ “addition of mycophenolate mofetil (MMF) to a calcineurin” PMID 15023160 ↗ Apr 2004 “mycophenolate mofetil(MMF) combined with tacrolimus(TAC)” NCT05916781 ↗ “Mycophenolate mofetil (MMF) increases HCV viral load.” NCT01134952 ↗ “maintenance therapy with Mycophenolate Mofetil (MMF)” NCT05063513 ↗ “Four participants took mycophenolate mofetil (MMF).” PMID 36519118 ↗ Nov 2022 “Mycophenolate mofetil (MMF) on days +5 through +25” NCT03922724 ↗ “Mycophenolate Mofetil (MMF) for GVHD prophylaxis.” NCT00763490 ↗ “Mycophenolate mofetil (immunosuppressant, MMF)” NCT00189150 ↗ “Oral CellCept® (Mycophenolate Mofetil, MMF)” NCT02630563 ↗ “1 g mycophenolate mofetil [MMF] twice daily” PMID 31509331 ↗ Oct 2019 “Mycophenolate mofetil (MMF) 15 mg/kg PO TID” NCT04187105 ↗ “everolimus plus mycophenolate mofetil (MMF)” NCT03596970 ↗ “This group receive oral MMF of 2.0 g / d.” NCT03580291 ↗ “Drug Name: Mycophenolate Mofetil (MMF)” NCT04402580 ↗ “CellCept® (mycophenolate mofetil- MMF)” NCT01436305 ↗ “Mycophenolate Mofetil (MMF) Treatment” NCT07675291 ↗ “Mycophenolate Mofetil (MMF) Treatment” NCT06288932 ↗ “prescribe mycophenolate mofetil(MMF)” NCT04147390 ↗ “Mycofenolate Mofetil (MMF) 500mg/bid” NCT04936971 ↗ “Drug: Mycophenolate mofetil (MMF)” NCT00916045 ↗ “Drug: Mycophenolate Mofetil (MMF)” NCT00239005 ↗ “Drug: Mycophenolate Mofetil (MMF)” NCT06799195 ↗ “Drug: Mycophenolate mofetil(MMF)” NCT02532777 ↗ “Drug: Mycofenolate Mofetil (MMF)” NCT00451867 ↗ “Drug: mycophenolate mofetil(MMF)” NCT02137239 ↗ “• Mycophenolate mofetil (MMF)” NCT07124078 ↗ “* Mycophenolate mofetil (MMF)” NCT02988466 ↗ “mycophenolate mofetil (MMF)” PMID 42066960 ↗ Apr 2026 “Mycophenolate mofetil (MMF)” NCT01154387 ↗ “mycophenolate mofetil (MMF)” PMID 35224732 ↗ Feb 2022 “Mycophenolate Mofetil (MMF)” NCT00455013 ↗ “Mycophenolate Mofetil (MMF)” NCT03943147 ↗ “Mycophenolate Mofetil (MMF)” NCT02390362 ↗ “mycophenolate mofetil (MMF)” NCT00038272 ↗ “Mycophenolate mofetil (MMF)” NCT06615050 ↗ “Mycophenolate Mofetil (MMF)” NCT03674411 ↗ “Mycophenolate Mofetil (MMF)” NCT00318474 ↗ “mycophenolate mofetil (MMF)” NCT00006233 ↗ “Mycophenolate mofetil (MMF)” NCT07214688 ↗ “Mycophenolate Mofetil (MMF)” NCT01580865 ↗ “Mycophenolate Mofetil (MMF)” NCT00571662 ↗ “Mycophenolate mofetil (MMF)” NCT01861106 ↗ “mycophenolate mofetil (MMF)” NCT04311632 ↗ “Mycophenolate mofetil (MMF)” NCT00430677 ↗ “mycophenolate mofetil (MMF)” NCT02053545 ↗ “Mycophenolate Mofetil (MMF)” NCT03663335 ↗ “Mycophenolate mofetil (MMF)” NCT02081183 ↗ “Mycophenolate Mofetil (MMF)” NCT03842696 ↗ “Mycophenolate Mofetil (MMF)” NCT03221257 ↗ “Mycophenolate mofetil (MMF)” NCT04339777 ↗ “Mycophenolate mofetil (MMF)” NCT00482053 ↗ “mycophenolate mofetil (MMF)” NCT02091414 ↗ “Mycophenolate mofetil (MMF)” NCT07634536 ↗ “Mycophenolate mofetil (MMF)” NCT00185640 ↗ “Mycophenolate mofetil (MMF)” NCT01056822 ↗ “Mycophenolate Mofetil (MMF)” NCT00555321 ↗ “mycophenolate mofetil (MMF)” NCT04927390 ↗ “mycophenolate mofetil (MMF)” NCT04376827 ↗ “Mycophenolate Mofetil (MMF)” NCT06279494 ↗ “Mycophenolate mofetil (MMF)” NCT03112603 ↗ “Mycophenolate mofetil (MMF)” NCT07340463 ↗ “Mycophenolate mofetil (MMF)” NCT00035555 ↗ “Mycophenolate Mofetil (MMF)” NCT01350245 ↗ “Mycophenolate mofetil (MMF)” NCT02187900 ↗ “Mycophenolate mofetil (MMF)” NCT02217410 ↗ “mycophenolate mofetil， MMF” NCT06557174 ↗ “MMF” NCT03670966 ↗ “MMF” NCT01527045 ↗ “MMF” NCT05000216 ↗ “MMF” NCT04904588 ↗ NCT00611494 ↗ NCT04221477 ↗ NCT00956059 ↗ NCT01128335 ↗ NCT00001964 ↗ NCT00768729 ↗ NCT05627557 ↗ NCT03663933 ↗ NCT04203108 ↗ NCT01544491 ↗ NCT00724022 ↗
Known as	MPM	“This study will compare the safety and effectiveness of two drugs-methotrexate and mycophenolate mofetil (MPM)-in preventing disease recurrence in patients with Wegener's...” NCT00004567 ↗ 1 “This study will examine the safety and effectiveness of the drug mycophenolate mofetil (MPM) in treating Wegener's granulomatosis and related inflammatory vessel diseases.” NCT00001764 ↗
Known as	My-rept capsule	“assistant is My-rept capsule®(Mycophenolate Mofetil)” NCT02075242 ↗
Known as	Mycofenolate mofetil	“Mycofenolate mofetil (MMF) (for Group A)” NCT02540395 ↗ 2 “Mycofenolate Mofetil (MMF) 500mg/bid” NCT04936971 ↗ NCT06828796 ↗
Known as	Mycofit	“mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax)” NCT06297096 ↗
Known as	Mycophenoate Mofetil	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02686619 ↗
Known as	Mycophenolat Mofetil	“Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day” NCT00785330 ↗ 4 NCT00223015 ↗ NCT00223028 ↗ NCT00402532 ↗ NCT00687180 ↗
Known as	mycophenolate mofetil (MMF)	“• Mycophenolate mofetil (MMF)” NCT06821542 ↗ 7 “mycophenolate mofetil (MMF)” NCT01707004 ↗ NCT00185614 ↗ NCT00568633 ↗ NCT03734601 ↗ NCT00972101 ↗ NCT01843348 ↗ NCT02936505 ↗
Known as	Mycophenolate Mofetil Dispersible tablets（CYCOPIN）	“Mycophenolate Mofetil Dispersible tablets（CYCOPIN®）” NCT04048161 ↗
Known as	Mycophenolate Mofetil Hydrochloride	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04469842 ↗
Known as	Mycophenolate mofetil, CellCept(R)	“Mycophenolate mofetil, CellCept(R)” NCT00360685 ↗
Known as	Mycophenolate Mofetil/Sodium	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06478017 ↗
Known as	Mycophenolatmofetile	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00359814 ↗ 1 NCT00359658 ↗
Known as	Mycophenylate mofetil	“In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD” NCT00143559 ↗ 4 NCT01095172 ↗ NCT00186628 ↗ NCT01962636 ↗ NCT00383448 ↗
Known as	Mycophénolate mofétil = Cellcept	“Mycophénolate mofétil = Cellcept” NCT00538265 ↗ 3 “mycophenolate mofetil (Cellcept)” NCT01005706 ↗ “mycophenolate mofetil / CellCept” NCT00299221 ↗ “mycophenolate mofetil (Cellcept)” NCT00132691 ↗
Known as	Myfenax	“mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax)” NCT06297096 ↗
Known as	Myfortic	“Mycophenolate mofetil (CellCept or Myfortic) belongs to a class of medications known as immunosuppressives.” NCT02370693 ↗
Known as	◦Drug: Mycophenolate mofetil	“◦Drug: Mycophenolate mofetil” NCT01983761 ↗
Action	Inhibit	“In this study we try to inhibit the activation of the immune system with mycophenolate mofetil (MMF).” NCT00120419 ↗
Modality	Small molecule	“a morpholinoethyl ester of mycophenolic acid” NCT05113004 ↗
Route	Oral	“Patients with active disease will be given MPM and prednisone, both in tablet form.” NCT00001764 ↗